<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9420909</article-id><article-id pub-id-type="pmcid-ver">PMC9420909.1</article-id><article-id pub-id-type="pmcaid">9420909</article-id><article-id pub-id-type="pmcaiid">9420909</article-id><article-id pub-id-type="pmid">36045689</article-id><article-id pub-id-type="doi">10.3389/fimmu.2022.952229</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Heterologous immunity induced by 1<sup>st</sup> generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="RS">Raj S.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1834476"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Agrawal</surname><given-names initials="B">Babita</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/479303"/></contrib></contrib-group><aff id="aff1">
<institution>Department of Surgery, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta</institution>, <addr-line>Edmonton, AB</addr-line>, <country>Canada</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Alexandra J. Spencer, University of Oxford, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ottavia Maria Delmonte, National Institutes of Health (NIH), United States; Arpan Acharya, University of Nebraska Medical Center, United States</p></fn><corresp id="fn001">*Correspondence: Babita Agrawal, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bagrawal@ualberta.ca">bagrawal@ualberta.ca</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">399856</issue-id><elocation-id>952229</elocation-id><history><date date-type="received"><day>24</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>08</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>30</day><month>08</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-05 04:25:16.467"><day>05</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Patel and Agrawal</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Patel and Agrawal</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-13-952229.pdf"/><abstract><p>Severe acute respiratory syndrome virus-2 (SARS-CoV-2), the causative infectious agent of the COVID-19 pandemic, has led to multiple (4-6) waves of infections worldwide during the past two years. The development of vaccines against SARS-CoV-2 has led to successful mass immunizations worldwide, mitigating the worldwide mortality due the pandemic to a great extent. Yet the evolution of new variants highlights a need to develop a universal vaccine which can prevent infections from all virulent SARS-CoV-2. Most of the current first generation COVID-19 vaccines are based on the Spike protein from the original Wuhan-hu-1 virus strain. It is encouraging that they still protect from serious illnesses, hospitalizations and mortality against a number of mutated viral strains, to varying degrees. Understanding the mechanisms by which these vaccines provide heterologous protection against multiple highly mutated variants can reveal strategies to develop a universal vaccine. In addition, many unexposed individuals have been found to harbor T cells that are cross-reactive against SARS-CoV-2 antigens, with a possible protective role. In this review, we will discuss various aspects of natural or vaccine-induced heterologous (cross-reactive) adaptive immunity against SARS-CoV-2 and other coronaviruses, and their role in achieving the concept of a pan-coronavirus vaccine.</p></abstract><kwd-group><kwd>heterologous immunity</kwd><kwd>pan-coronavirus vaccine</kwd><kwd>universal vaccine development</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Canadian Institutes of Health Research
</institution><institution-id institution-id-type="doi">10.13039/501100000024</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">PJT165854</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><equation-count count="0"/><ref-count count="212"/><page-count count="23"/><word-count count="14124"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Coronaviruses (CoVs) are a diverse family of enveloped, positive sense, single-stranded RNA viruses whose natural hosts are bats and other mammalian species (<xref rid="B1" ref-type="bibr">1</xref>). Four genera of coronaviruses exist, <italic toggle="yes">Alphacoronavirus, Betacoronavirus, Gammacoronavirus</italic>, and <italic toggle="yes">Deltacoronavirus</italic>, of which <italic toggle="yes">Alpha-</italic> and <italic toggle="yes">Beta-coronaviruses</italic> are most effective at causing respiratory pathologies and disease in humans (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Since the beginning of the 21<sup>st</sup> century, three highly pathogenic strains of beta-coronaviruses have crossed the species barrier to cause zoonotic diseases with high transmissibility and mortalities in humans: severe acute respiratory syndrome virus (SARS-CoV-1) in 2002, Middle Eastern respiratory syndrome virus (MERS-CoV) in 2012, and most recently, severe acute respiratory syndrome virus 2 (SARS-CoV-2) in 2019 (<xref rid="B3" ref-type="bibr">3</xref>). The first case of SARS-CoV-2 was reported in Wuhan, China by the Wuhan Municipal Health Commission on 31 December 2019 (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Due to the rapid spread of the virus across the globe, the World Health Organization (WHO) declared SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19) pandemic in March 2020. Ongoing efforts against SARS-CoV-2 with 1<sup>st</sup> generation COVID-19 vaccines (Pfizer/BioNTech-BNT162b2, Moderna-mRNA-1273, AstraZeneca-ChAdOx1nCov-18, Johnson &amp; Johnson-Ad26.COV2-S) and the implementation of booster shots have reduced death tolls, hospitalizations, and mitigated severe pathologies associated with COVID-19 disease. Additionally, non-pharmaceutical based interventions such as social distancing, wearing masks, frequent handwashing, and quarantine practices have contributed to slowing the spread of the virus. However, the emergence of increasingly pathogenic and transmissible SARS-CoV-2 variants has prolonged the pandemic. As of April 2022, there are &gt;500,000,000 confirmed cases of COVID-19 and &gt;6,000,000 deaths related to COVID-19 globally (<xref rid="B6" ref-type="bibr">6</xref>). As the pandemic continues, protection acquired from natural infection and/or vaccine-induced immunity has been steadily declining (<xref rid="B7" ref-type="bibr">7</xref>). Besides specific immunity induced by vaccines, an untapped mechanism of protection, known as heterologous immunity, can provide insight into protective mechanisms of long lasting, cross-variant immunity, and impact the design, development, and implementation of future generations of COVID-19 vaccines.</p><p>Heterologous immunity is acquired when the immune response to one pathogen influences the outcome of an infection with unrelated pathogens (<xref rid="B8" ref-type="bibr">8</xref>). Heterologous immunity arises from the fundamental characteristics of the adaptive immune system of specificity and memory that allows a quick and efficient response towards previously encountered pathogens or challenges. Immunological memory implies the establishment of lymphocyte populations that can become quickly reactivated upon secondary infection, promoting long-term, sustainable, protective responses. Specificity allows the selection and expansion of epitope-specific T/B cell populations that drive the ability to mount a robust pathogen-specific response against previously encountered pathogens (<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B10" ref-type="bibr">10</xref>). Inducing heterologous immunity is centred on promiscuous pathogen-specific T/B cell memory responses that respond against epitopes that may or may not share similarities with other unrelated pathogens. In other words, heterologous immunity supports the idea that pathogen-specific memory responses can mount a robust response against a novel, never-before-seen pathogen <italic toggle="yes">via</italic> a mechanism of cross-reactivity. Heterologous immunity allows the cross-reactivity of immune responses and its range in detecting pathogens that are cross-variant, cross-species, or even cross-kingdom. A study by Youssef et&#160;al. identified a Hyrl antigen specific IgM antibody from a fungal infection, <italic toggle="yes">Candida albicans</italic>, that was able to cross-react with two Gram-negative bacteria, <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic> (<xref rid="B11" ref-type="bibr">11</xref>). The study found there was structural homology between the hypha-regulated protein (Hyr1) of <italic toggle="yes">C. albicans</italic> and the cell surface protein of <italic toggle="yes">A. baumannii.</italic> Furthermore, the study found that active vaccination with Hyr1p-N protein or passive immunization with the IgM antibody to that protein protects mice from <italic toggle="yes">A. baumannii</italic> infections and prevents severe bacteremia (<xref rid="B11" ref-type="bibr">11</xref>). This IgM antibody illustrates a cross-kingdom humoral response that is not only capable of cross-reacting with both a bacterial and fungal protein, but is also functionally protective against <italic toggle="yes">A. baumannii</italic> infections and their pathologies. Additional studies on cross-reactive antibodies and T cell responses among <italic toggle="yes">Plasmodium</italic> species, influenza viruses, and flaviviruses are leading vaccine development in a new direction (<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). This new approach explores vaccine-induced immunity not only against the targeted pathogen, but also towards closely related, and even distantly pathogens. Therefore, vaccine development efforts also need to emphasize towards a universal vaccine that broadly protects against the targeted pathogens and its cross-reactive counterparts.</p></sec><sec id="s2"><title>SARS-CoV-2 Origin</title><p>SARS-CoV-2 (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1A</bold>
</xref>) is a member of the family, <italic toggle="yes">Coronaviridae</italic> and genus, <italic toggle="yes">Betacoronaviruse</italic>&#8212;these viruses reside in bat reservoirs and commonly infect humans <italic toggle="yes">via</italic> zoonotic transmission (<xref rid="B15" ref-type="bibr">15</xref>). Epidemiological studies looking into sequence and amino-acid similarities between closely-related-SARS-CoV-2 coronaviruses have provided information about the zoonotic origins of SARS-CoV-2. The closest relative of SARS-CoV-2, RaTG13, was discovered from <italic toggle="yes">Rhinolophus affinis</italic> bats in Yunnan Province, China. It had 96.2% sequence similarity to the entire SARS-CoV-2 genome, but the RaTG13 genome lacked two critical regions: the receptor binding domain (RBD) and cleavage-site sequence (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). It was suggested that SARS-CoV-2 and RaTG13 diverged more than 30 years ago into two lineages where RaTG13 was a recombinant virus, and SARS-CoV-2 possessed the ancestral RBD trait that is shared among bat viruses (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Several reports of coronaviruses from different bat species around the Yunnan Province have shown similarities to SARS-CoV-2. RmYN02, discovered in <italic toggle="yes">Rhinolophus malayanus</italic> bats, shows a 97.2% sequence similarity to the open reading frame (orf)-1a and -1b, which is the largest orf in coronaviruses, extending 21,300 nucleotides (<xref rid="B16" ref-type="bibr">16</xref>). RpYN06, found in <italic toggle="yes">Rhinolophus pusillus</italic>, had 94.5% sequence identity to SARS-CoV-2 genome, and it is the closest related genomic backbone to SARS-CoV-2 known to date (<xref rid="B17" ref-type="bibr">17</xref>). Like MERS-CoV and SARS-CoV-1, SARS-CoV-2 has originated from bats; furthermore, fecal samples from domestic and wild animals suggested that an intermediate host may have played a role in the SARS-CoV-2 zoonosis (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>). Reports of closely related coronaviruses from Malaysian pangolins that were smuggled to Guangdong Province in China, exhibited 85.5-92.4% sequence similarity to the SARS-CoV-2 genome, and 97.4% amino-acid similarity to SARS-CoV-2 RBD with identical amino-acid residues in five critical RBD sites (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B21" ref-type="bibr">21</xref>). SARS-CoV-2-related-coronaviruses are known to reside in Malaysian pangolin populations and manifest similar disease outcomes as humans, therefore it is speculated that pangolins could have been an intermediate host for SARS-CoV-2 (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Collectively, these reports confirm SARS-CoV-2-related coronaviruses exist in wild animals, especially bat species (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B20" ref-type="bibr">20</xref>). The role of an intermediate host&#8212;if there is any&#8212;has not been conclusively proven as no direct ancestor of SARS-CoV-2 virus (which is expected to have more than 99% sequence similarity throughout the genome) has been found (<xref rid="B21" ref-type="bibr">21</xref>). Currently, the origin of SARS-CoV-2 is suggested to be a result of a cross-species recombination event between a bat and a pangolin coronavirus that subsequently crossed the species barriers to infect humans (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B21" ref-type="bibr">21</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Schematic Presentation of the SARS-CoV-2 Virion Structure and mRNA Genome. <bold>(A)</bold> The SARS-CoV-2 virion consists of the spike (S), nucleocapsid (N), envelope (E), and membrane (E) proteins<sup>22</sup>. The S, M, and E proteins make up the viral envelope, which is the outermost layer of the SARS-CoV-2 virion. The N protein is tightly bound with the SARS-CoV-2 mRNA genome and interacts with M-protein ensuring that proper packaging of the genome occurs within the virion. <bold>(B)</bold> The SARS-CoV-2 genome is a single stranded, positive-sense mRNA genome with a 5&#8217; cap and 3&#8217; poly-A-tail. The full SARS-CoV-2 genome translates 16 non-structural proteins (NSP1-16) from orf1a and orf1b, 9 accessory proteins from orf3a, orf3b, orf6, orf7a, orf7b, orf8, orf9b, orf9c, and orf10, and 4 structural proteins (S, E, M, and N).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-13-952229-g001.jpg"/></fig></sec><sec id="s3"><title>SARS-CoV-2 genome and structural/non-structural proteins</title><p>SARS-CoV-2 has a 30,000 nucleotide, positive sense, single stranded RNA genome defined by a 5&#8217;-cap and 3&#8217;-poly-A-tail (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1B</bold>
</xref>) (<xref rid="B22" ref-type="bibr">22</xref>). The 5&#8217; end of SARS-CoV-2 has a frameshift mechanism between orf1a and orf1b, which allows the synthesis of two polypeptides that are cleaved to produce 16 non-structure proteins (Nsp1-16). These proteins play an important role in the infectious cycle of SARS-CoV-2. Structural proteins such as Spike (S), Nucleocapsid (N), Membrane (M), and Envelope (E) are encoded at the 3&#8217;-end, (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1B</bold>
</xref>) (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). The SARS-CoV-2 genome is wrapped around the N protein, which is surrounded by a membrane consisting of the M, E and S proteins (<xref rid="B21" ref-type="bibr">21</xref>). Also, the 3&#8217; end of the genome encodes nine accessory proteins (orf3a, orf3b, orf6, orf7a, orf7b, orf8, orf9b, orf9c, orf10), which play a role in virulence and host interactions (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1B</bold>
</xref>) (<xref rid="B24" ref-type="bibr">24</xref>). These accessory proteins are not conserved as well as the structural proteins among coronaviruses, therefore, vaccine and therapeutic efforts focus mainly on the structural proteins of SARS-CoV-2 (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>).</p><p>In RNA viruses, like SARS-CoV-2, nucleotide changes occur at a higher rate compared to DNA viruses due to its erroneous replication process. This inefficiency alters genomic sequences and facilitates the proliferation of novel variants. The genomic alternations that increase viral fitness, such as enhancing viral entry, replication, immune evasion, and transmission, result in the increased number of the variants that have the desired genomic change (<xref rid="B26" ref-type="bibr">26</xref>). In addition to the faulty replication process, the SARS-CoV-2 genome has polymorphic sites concentrated at encoding regions at the 3&#8217; end, leading to more mutations in structural proteins (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). A 2006 study comparing 116 SARS-CoV genomes showed that regions encoding orf10/11, orf3/4, E, M and S proteins are subjected to higher mutation rates compared to other regions of the genome (<xref rid="B27" ref-type="bibr">27</xref>). More recently, Mohammad et&#160;al. found that emerging SARS-CoV-2 variants have the highest mutation rates in structural proteins in the following order: Spike &gt;Nucleocapsid &gt;Membrane &gt;Envelope proteins (<xref rid="B28" ref-type="bibr">28</xref>). Furthermore, they found that certain mutations in structural proteins were associated with advantageous effects on the infection cycle of SARS-CoV-2.</p><sec id="s3_1"><title>Spike protein</title><p>The spike protein is 1273 amino acids long with a molecular weight of 180-200 kDa. It is a type 1 fusion membrane protein, consisting of an extracellular N-terminus domain (NTD), an RBD, a cleavage site, a fusion peptide, two heptad repeats, a transmembrane domain, and a cytosolic C-terminus domain (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2A</bold>
</xref>) (<xref rid="B29" ref-type="bibr">29</xref>). The extracellular region of the spike protein is highly glycosylated. The S protein has two subunits, S<sub>1</sub> (14-685 aa residues) and S<sub>2</sub> (686-1273 aa residues), that dissociate <italic toggle="yes">via</italic> a host furin protease, at its cleavage site (<xref rid="B30" ref-type="bibr">30</xref>). In the infection cycle, the S protein is responsible for binding to the host angiotensin-converting enzyme 2 receptor (ACE2), and mediates membrane fusion which induces viral entry (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Mutations in the SARS-CoV-2 Spike Protein Among the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617), and Omicron (B.1.1.529) variants of concerns. <bold>(A)</bold> The figure shows the domains of the SARS-CoV-2 spike protein. The spike protein has two subunits, S<sub>1</sub> and S<sub>2</sub>; these subunits separate at the cleavage site. The S<sub>1</sub> subunit contains the N-terminus domain (NTD) and receptor-binding domain (RBD). The S<sub>2</sub> subunit has a fusion peptide, two heptad repeats, and a transmembrane domain. <bold>(B)</bold> The amino acid changes in the spike protein of 5 VOCs are depicted in the figure. The Alpha (B.1.1.7) variant contains these mutations in the spike protein: D614G, &#916;H69-V70, &#916;Y144, R203K, S235F, N501Y, A570D, P681H, T716I, S982A, and D1118H<sup>78,79</sup>. Beta (B.1.351) variant has the following mutations in the spike protein: D80A, D215G, K417N, E484K, N501Y, D614G and A701V<sup>90,91</sup>. Gamma (P.1) variant has L18F, T20N, P26S, D138Y, R190S, K417T/N, E484K, N501Y, D614G, H655Y, T1027I, and V1176F mutations in the spike protein<sup>98 98</sup>. The Delta (B.1.617) variant contains T19R, V70F, G142D, &#916;156-157, R158G, A222V, W258L, K417N, L452R, T478K, D614G, P681R, and D950N mutations in the spike protein<sup>105</sup>. The Omicron (B.1.1.529) variant has acquired over 32 mutations in the spike protein, including A67V, &#916;69-70, T95I, &#916;142-144, Y145D, &#916;211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F<sup>105</sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-13-952229-g002.jpg"/></fig><p>The variability observed in the SARS-CoV-2 variants is dominated by mutations in the RBD region of the S<sub>1</sub> subunit (<xref rid="B26" ref-type="bibr">26</xref>). The RBD region reflects evolutionary relativeness among coronaviruses between humans, cats, and swine species, yet this region is the least conserved (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Mutations in this region directly impact the binding affinity of the virus towards ACE2 and alters the interaction between the virus and target cell (<xref rid="B31" ref-type="bibr">31</xref>). RBD mutations are associated with changes in viral virulence, therefore some variants are more infectious than others. Mutations in the S<sub>2</sub> subunit have also been hypothesized to influence infectivity of SARS-CoV-2. The S<sub>2</sub> region relies on the efficiency of furin and serine proteases to access cleavage sites to mediates the fusion of viral and host membranes (<xref rid="B30" ref-type="bibr">30</xref>). Therefore, mutations in S<sub>2</sub> evolve to increase the number of furin and serine cleavage sites and/or increase susceptibility of cleavage events (<xref rid="B31" ref-type="bibr">31</xref>). The presence of multiple cleavage site in SARS-CoV-2 has significant implications on infectivity as the absence of these sites lead to a less infectious virus, such as SARS-CoV-1. Mutation in the Spike protein and their effects on virulence are discussed below.</p><p>In the highly mutating spike protein, the N501Y mutation, found in the B.1.1.7 (UK), B.1.128.1 (South Africa), B.1.351(Brazil), P.1 (Brazil) and B.1.1.529 (South Africa) variants, increased binding affinity of the RBD to ACE2 receptor (<xref rid="B32" ref-type="bibr">32</xref>&#8211;<xref rid="B34" ref-type="bibr">34</xref>). The amino acid substitution is located within the RBD region of the S<sub>1</sub> subunit and associated with increased infection rates. This mutation is one of the earliest changes detected in emerging SARS-CoV-2 variants mentioned. Similarly, the K417N substitution, found in the B.1.351 (South Africa, Beta variant), P.1 (Brazil), B.1.617 (India), and B.1.1.529 (South Africa) variants, significantly increased binding affinity of spike to ACE2 (<xref rid="B35" ref-type="bibr">35</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>). In addition, K417N contributed to immune evasion by reducing antibody binding affinities against RBD (<xref rid="B38" ref-type="bibr">38</xref>). The E484K mutation was found in the B.1.351 (South Africa, Beta variant), P.1 (Brazil), P.2 (Zeta), B.1.525 (Eta), and B.1.526 (Iota) variants (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>). The amino acid change alters the electrostatic interactions between antibodies and RBD, decreasing the neutralization capability of SARS-CoV-2 polyclonal serum (<xref rid="B39" ref-type="bibr">39</xref>&#8211;<xref rid="B41" ref-type="bibr">41</xref>). L452R and L18F mutations were associated with similar effects as K417N, in evading the host humoral response against SARS-CoV-2 (<xref rid="B39" ref-type="bibr">39</xref>&#8211;<xref rid="B41" ref-type="bibr">41</xref>).</p><p>Additionally, the spike protein has mutations that influence the S protein dissociation and cleaving processes. For example, A570D was first found in the B.1.1.7 (UK) variant that induced a conformational change, along with D614G, that destabilizes the S protein (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Another mutation, S982A, found in the B.1.1.7(UK) and P.3 (Japan/Philippines) variants prevented the formation of hydrogen bonds between S<sub>1</sub> and S<sub>2</sub> subunits, increasing the likeliness of these subunits to dissociate (<xref rid="B44" ref-type="bibr">44</xref>). Mutations directly involved in the furin cleaving process were characterized by P681H and D614G changes and associated with higher infectivity and replication rates of SARS-CoV-2 (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B45" ref-type="bibr">45</xref>). All in all, the spike is a highly variable protein that significantly impacts SARS-CoV-2&#8217;s ability to infect target cells (<xref rid="B28" ref-type="bibr">28</xref>). The 1<sup>st</sup> generation COVID-19 vaccines are spike-based which have been effective in mitigating COVID-19 associated pathologies, hospitalizations, and deaths. Generally, spike-based immunity has been defined as neutralizing as it prevents the virus from entering targeted host cells. Evidently, during the pandemic, the spike protein has acquired many mutations (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>), and this results in the decline of vaccine-induced immunity. For future vaccines and longer-lasting immunity, it may be important to consider other proteins and antigen targets that are conserved and have lower tendencies to acquire mutations.</p></sec><sec id="s3_2"><title>Envelope protein</title><p>The envelope protein is ~75 amino acid residues long with a molecular weight of 8-12 KDa, consisting of a hydrophilic extracellular N-terminus, followed by a hydrophobic transmembrane domain, and cytoplasmic C-terminus (<xref rid="B46" ref-type="bibr">46</xref>). The envelope protein is responsible for the activation of inflammasomes, and the budding and release of the viral progeny (<xref rid="B47" ref-type="bibr">47</xref>). In addition to these functions, the envelope protein forms a pentameric ion channel with low ion selectivity, called a viroporin (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Many animal studies have suggested that the viroporin plays an important role in virulence and have shown that its ion channel activity is directly proportional to SARS-CoV-2 pathogenesis (<xref rid="B47" ref-type="bibr">47</xref>&#8211;<xref rid="B49" ref-type="bibr">49</xref>). In mouse models, knocking out the envelope gene was found to have no impact on SARS-CoV-2 viral replication, but it reduced edema (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Many animal studies, where the virus lacks viroporin activity, show reduced IL-1&#946;, TNF-&#945; and IL-6 production in the lungs (<xref rid="B47" ref-type="bibr">47</xref>). It is suggested that viroporins and their ion channel activity are linked to the development of cytokine storm and acute respiratory distress syndrome (ARDS).</p><p>The envelope protein is a highly conserved protein among various members of coronaviruses, therefore, very few mutations are observed in the E protein (<xref rid="B46" ref-type="bibr">46</xref>). Surveying all the SARS-CoV-2 variants, B.1.351 (South Africa, Beta variant) had a P71L mutation in the envelope protein that associated with disease severity and death rate (<xref rid="B51" ref-type="bibr">51</xref>). The low variability of the envelope protein makes it an attractive target as a vaccine and therapeutic target, as many circulating viral variants would be vulnerable. Also, the ion channel activity associated with pathogenesis makes the protein immunogenic and potentially capable of inducing a robust immune response. A conserved, immunogenic protein, like the E protein, can be a potential target for immunotherapeutics or vaccine candidates.</p></sec><sec id="s3_3"><title>Membrane protein</title><p>The membrane protein is a glycoprotein, 222 amino acid residues long, and the most translated protein (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B52" ref-type="bibr">52</xref>). The membrane protein is a self-formulating protein that interacts with all structural proteins (S, E and N) to form virus-like particles (VLP) (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B53" ref-type="bibr">53</xref>). The membrane protein is involved in stabilizing the interaction between genomic mRNA and the N-protein complex to incorporate the SARS-CoV-2 genome into the virion (<xref rid="B46" ref-type="bibr">46</xref>). Protein-protein interactions between M and other structural proteins allow the trafficking of these proteins for assembly and release. Lastly, the membrane protein is involved in the budding and release of the newly synthesized virions.</p><p>Evolutionarily, the M protein has been conserved across <italic toggle="yes">Beta-coronaviruses</italic> providing a common viral structural protein for all viruses within the genus (<xref rid="B54" ref-type="bibr">54</xref>). Genomic sequencing reports have shown more than 97% homology between M sequences of SARS-CoV-2 variants sampled (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). Troyano-Hern&#225;ez et&#160;al. surveyed 103,419 SARS-CoV-2 M sequences, and reported 99.99% conservation, with only 291aa changes found (<xref rid="B55" ref-type="bibr">55</xref>). Out of 291 aa changes, only two mutations were presented in significantly higher frequencies: D3G (0.7%, in 724 sequences) and T175M (1%, in 1026 sequences). The D3G mutation first emerged out of Africa and South Africa, and the T175M was discovered in Europe. Another study surveyed 5677 GenBank records and found that 5557 sequences had no mutations or synonymous mutations, while the other 120 sequences had non-synonymous mutations in the M protein (<xref rid="B56" ref-type="bibr">56</xref>). Furthermore, the study found 10 mutations (C64F, A69S, A69V, V70F, N113B, R158L, V170I, D190N, D209Y and S214I) in the M protein that are predicted to change secondary protein structure. All in all, the M protein has evolved and incorporated mutations, but it is largely conserved across <italic toggle="yes">Betacoronaviruses</italic> and SARS-CoV-2 variants. With the M protein being involved in integral parts of the infection cycle, such as virus assemble, protein trafficking, and dictating protein-protein interaction of SARS-CoV-2 structural proteins, any major changes can result in detrimental effects on the overall fitness of the virus. Vaccine and immunotherapeutic targeting the SARS-CoV-2 membrane protein can potentially induce immune responses that can cross-react with various SARS-CoV-2 variants and other <italic toggle="yes">Betacoronaviruses</italic> because of the high sequence homology in the M protein.</p></sec><sec id="s3_4"><title>Nucleocapsid protein</title><p>The nucleocapsid protein is 419 aa residues long (<xref rid="B57" ref-type="bibr">57</xref>). It consists of a N-(NTD) and C-terminus domain (CTD) connected by a serine/arginine linker region (LKR). The N protein helps package the viral RNA genome and ensures proper replication and viral assembly processes take place. The LKR allows the N protein to oligomerize with other N-proteins and exposes the RNA-binding domains, located within the NTD/CTD, to bind to the viral genome (<xref rid="B58" ref-type="bibr">58</xref>&#8211;<xref rid="B60" ref-type="bibr">60</xref>). In this process, serine/arginine amino acids will stabilize the interaction between the N protein and RNA genome forming a stable ribonucleoprotein complex, called a capsid (<xref rid="B58" ref-type="bibr">58</xref>). The role of the viral capsid is to protect the viral genome from environmental conditions and host immune responses. It also plays an important role in delivery of the genetic contents into targeted cells.</p><p>Among coronaviruses, the N protein has been largely conserved, except for certain regions. There is 90% sequence identity between the SARS-CoV-2 and SARS-CoV-1 N proteins (<xref rid="B61" ref-type="bibr">61</xref>). Within the N protein sequence, the LKR (182-247 aa residues) accounts for the majority of the mutations in the SARS-CoV-2 variants. These mutations are located around multiple, highly phosphorylated sites that influence N protein thermodynamic properties and have a major impact on the viral life cycle. The R203K mutation is located in the LKR region and was first discovered in the B.1.1.7 (UK) and P.1 (Brazil) variants (<xref rid="B62" ref-type="bibr">62</xref>). This mutation coincides with G204R and has been found to increase overall expression levels of the N protein and various sub-genomic RNA transcripts (<xref rid="B63" ref-type="bibr">63</xref>). Structurally, the 203/204 mutations increase entropy and intrinsic disorder causing changes to the N protein oligomerization process (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Next, the T205I mutation was first observed in the B.1.351(South Africa) variant (<xref rid="B63" ref-type="bibr">63</xref>). It is a highly phosphorylated site within the LKR. This mutation alters the activation of the N protein resulting in decreased fitness of the virus, however the T205I mutation was reported 43% of the time in B.1.351 variants. Lastly, the S235F mutation was reported in the B.1.1.7 (UK) variant (<xref rid="B63" ref-type="bibr">63</xref>). The S235F mutation is unique in that it is associated with immune evasion. The mutation alters a highly targeted B cell epitope, thereby decreasing the specificity of certain antibodies to mount a response against SARS-CoV-2 N protein (<xref rid="B63" ref-type="bibr">63</xref>). Immunity against the SARS-CoV-2 N protein is governed by CD4<sup>+</sup> T cells, and they have been shown to cross-react with other endemic coronaviruses (<xref rid="B28" ref-type="bibr">28</xref>).</p></sec></sec><sec id="s4"><title>Emergence of SARS-CoV-2 variants</title><p>SARS-CoV-2 is an evolving virus that manifests a vast number of mutations. Mutations can be induced by errors in replication, however to explain the accelerated proliferation of SARS-CoV-2 variants, two other sources of mutations need to acknowledge: host RNA editing and modification mechanisms, and genetic recombination events (<xref rid="B64" ref-type="bibr">64</xref>). RNA editing and modification enzymes, including apolipoprotein B mRNA editing catalytic polypeptide-like enzyme (APOBEC) and adenosine RNA specific 1 enzyme (ADAR1), are host innate anti-viral mechanisms designed to detect viral RNA and alter nucleotide sequences (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>). These RNA enzymes can induce cytosine-to-uracil and adenosine-to-inosine nucleotide substitutions in the genomic sequence resulting in translated viral proteins that are dysfunctional (<xref rid="B66" ref-type="bibr">66</xref>). Next, phylogenetic studies have revealed that SARS-CoV-2 variants are most likely to have emerged because of recombination events (<xref rid="B67" ref-type="bibr">67</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>). Evidence shows that multiple SARS-CoV-2 variants can infect a host, making it more likely that variants can exchange genetic material (<xref rid="B70" ref-type="bibr">70</xref>). A UK study found that circulating viruses, from late 2020 to early 2021, were recombinant viruses derived from the B.1.1.7 variant (<xref rid="B71" ref-type="bibr">71</xref>). Genomic analysis confirmed the recombination events occurred between ancestral B.1.1.7 and non-B.1.1.7 circulating virus as the recombinant viral genomes acquired single-nucleotide polymorphisms and deletions that define the B.1.1.7 lineage and other non-B.1.1.7 lineage mutations and variations (<xref rid="B71" ref-type="bibr">71</xref>). These modifications allow the virus to accumulate mutations and potentially give rise to novel variants. However, viruses have evolved to exploit these RNA enzymes to reach higher evolutionary potential by accumulating and selecting for advantageous mutations.</p><p>The WHO continuously monitors the evolution of SARS-CoV-2 and assesses the risk associated with emerging SARS-CoV-2 variants to global public health (<xref rid="B72" ref-type="bibr">72</xref>). SARS-CoV-2 variants are categorized into two groups: variants of interest (VOI) and variants of concern (VOC), based on its threat to public health. VOIs are associated with genetic mutations that could affect transmission, diagnosis, treatment and vaccine escape, but cause unique outbreak clusters of cases and have limited prevalence or expansion in many countries. However, VOCs are a major concern for public health as variants are associated with higher transmissibility and expansion in population, increased disease severity, hospitalizations and deaths, and significantly reduced vaccine efficacy rates and/or diagnostic detection failures. All variants of SARS-CoV-2 can be tracked back to the original wild-type strain, Wuhan-Hu-1, isolated in Wuhan in December 2019 that initiated the COVID-19 pandemic. The VOCs that emerged from the Wuhan-Hu-1 SARS-CoV-2 strain are discussed below (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>).</p><sec id="s4_1"><title>B.1.1.7 (Alpha) lineage</title><p>The B.1.1.7 variant was first discovered in the UK on September 20, 2020 (<xref rid="B73" ref-type="bibr">73</xref>). The virus consisted of several novel spike mutations, including 17 non-synonymous, six synonymous, and two deletions: &#916;H69-V70, &#916;Y144, R203K, S235F, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>) (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B73" ref-type="bibr">73</xref>). Three of the mutations in the S protein that were reported to be concerning due to an increase in viral transmission, pathogenicity, infectivity, and decreased susceptibility to neutralizing antibodies (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B72" ref-type="bibr">72</xref>&#8211;<xref rid="B77" ref-type="bibr">77</xref>). These mutations included the previously discussed N501Y and P681H mutations, and the &#916;H69-V70 deletion (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B34" ref-type="bibr">34</xref>). The &#916;H69-V70 deletion, located in the RBD, led to a conformational change in the S protein that evaded the host immune response (<xref rid="B78" ref-type="bibr">78</xref>). Additionally, a peer-reviewed study reported a 75% increase in transmissibility of the B.1.1.7 variant compared to the Wuhan-Hu-1 strain (<xref rid="B74" ref-type="bibr">74</xref>). Within three months, the B.1.1.7 variant was the predominant circulating strain in the UK and spreading across 114 countries (<xref rid="B74" ref-type="bibr">74</xref>&#8211;<xref rid="B77" ref-type="bibr">77</xref>). In terms of diagnosis, Public Health England reported that the B.1.1.7 mutations in the S gene alluded the RT-PCR detection assay&#8212;which amplifies the S gene to detect COVID-19 positivity in sick patients (<xref rid="B79" ref-type="bibr">79</xref>). In March 2021, Ontario&#8217;s COVID-19 Science Advisory Committee reported that 67% of COVID-19 cases were due to the B.1.1.7 variant (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>). These cases were associated with a 63% increase in hospitalization risk, 103% increase in intensive care admissions related to COVID-19 and 56% increase in mortalities (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B81" ref-type="bibr">81</xref>). With increased infectivity and transmissibility, the B.1.1.7 variant was reported to target younger age groups in Canada, between ages 20-30 y and up to 59 y (<xref rid="B82" ref-type="bibr">82</xref>).</p></sec><sec id="s4_2"><title>B.1.351 (Beta) lineage</title><p>The B.1.351 emerged from South Africa in October 2020 (<xref rid="B83" ref-type="bibr">83</xref>). From October 2020 to February 2021, the variant had spread to over 40 countries, including South Africa, Philippines, USA, Canada, and several EU countries. This lineage is defined by multiple mutations in Spike, including L18F, D80A, D215G, &#916;241-243, K417N, E484K, N501Y, D614G and A701V (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>) (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). Other mutations in N, E and orf1a proteins, include T205I, P71L and K1655N substitutions, respectively (<xref rid="B83" ref-type="bibr">83</xref>). In these B.1.351 variants, E484K and K417N mutations were concerning as they compromised neutralizing responses established from natural SARS-CoV-2 infections and/or vaccine-induced immune responses (<xref rid="B85" ref-type="bibr">85</xref>). Many studies reported that E484K, K417N and N501Y mutations can escape vaccine induced neutralizing antibody responses, as much as 3-5 folds (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>). In addition to immune evasion, the B.1.351 variant was 50% more infectious compared to its ancestor, as it dominated the second wave in South Africa, infecting more than 1.3 million people and causing 37,000 deaths (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B89" ref-type="bibr">89</xref>). Surges in B.1.351 cases demonstrated that the variant was more transmissible and infectious, but no evidence of increased severity was reported. In a molecular study, it was determined that sensitivity of the RT-PCR diagnostic test was not affected by the B.1.351 variant (<xref rid="B90" ref-type="bibr">90</xref>).</p></sec><sec id="s4_3"><title>P.1 (Gamma) variant</title><p>The P.1 lineage emerged out of Brazil in December 2020. It incorporated 17 non-synonymous mutations, 3 deletions, 4 synonymous mutations and one four-nucleotide insertion. Mutations located in the S protein were L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>) (<xref rid="B91" ref-type="bibr">91</xref>). Other mutations included, P80R in the N protein, S1188L and K1795Q in orf1ab, G174C in orf3a, E92K in orf8, two-nucleotide deletions at positions 11288/9, deletion in the nsp6 protein (S106del, G107del, and F108del), and a four-nucleotide insertion at the orf8/N intergenic region (ins28263) (<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B97" ref-type="bibr">97</xref>). The triple mutation in Spike protein of K417T, E484K, and N501Y retained its function of evading both vaccine-induced and natural-infection acquired immunity. In its entirety, the spike mutations in the P.1 lineage associated with higher affinity for ACE2 receptor compared to non-P.1 lineages. This potentially led to a 2.5-fold increase in transmission compared to previously circulating variants and had a reinfection probability of 6.4% (<xref rid="B93" ref-type="bibr">93</xref>). From December 2020 to January 2021, the P.1 variant became the dominant variant in Manaus, Brazil as 85% of genotyped samples were found to be P.1 positive (<xref rid="B93" ref-type="bibr">93</xref>&#8211;<xref rid="B95" ref-type="bibr">95</xref>). The WHO announced the P.1 lineage as a VOC, due to its increased transmissibility and its propensity to re-infect individuals.</p></sec><sec id="s4_4"><title>B.1.617 (Delta) lineage</title><p>The B.1.617 lineage emerged out of India in December 2021 (<xref rid="B98" ref-type="bibr">98</xref>). The S protein lineage-defining mutations include, T19R, V70F, G142D, &#916;156-157, R158G, A222V, W258L, K417N, L452R, T478K, D614G, P681R, and D950N (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>) (<xref rid="B98" ref-type="bibr">98</xref>). Researchers identified two potential mutations, L452R and E484Q, previously reported in B.1.1.7/B.1.351 and B.1.427/B.1.429 variants, respectively, as the reason for the exponential infectivity and immune evasion ability of B.1.617 variants (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B99" ref-type="bibr">99</xref>). Many viral fitness parameters were enhanced by the acquired mutations in the B.1.617 (Delta) variant. The onset of symptoms after exposure shortened from an average of 16.7 days to 10.3 days in unvaccinated individuals, indicating an enhanced replication ability of the B.1.617 lineage (<xref rid="B99" ref-type="bibr">99</xref>&#8211;<xref rid="B102" ref-type="bibr">102</xref>). A study in India reported that B.1.617 infections were associated with higher viral load and shedding as B.1.617 infections (n=47; Mean Ct: 16.5 cycles) has lower cycle thresholds compared to non-B.1.617 infections (n=22; Mean Ct: 19 cycles) (<xref rid="B103" ref-type="bibr">103</xref>). According to the Centre for Disease Control and Prevention (CDC), the reproduction number (R<sub>0</sub>) was between 5-9 for the lineage; in other words, the variant could be more transmissible than other viruses, such as Smallpox, Influenza, MERS, and SARS (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B104" ref-type="bibr">104</xref>). Moreover, the P681R mutation, previously identified in B.1.1.7 variants, was reported to increase fusion activity <italic toggle="yes">via</italic> enhanced furin cleaving which could possibly be contributing to the increased infectivity and transmissibility seen in the B.1.617 variant (<xref rid="B27" ref-type="bibr">27</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>). In relation to disease severity, one study showed infection with the B.1.617 variant in hamsters caused a higher viral load in the lungs, substantial lung lesions and weight loss, compared to other B.1 variants (<xref rid="B105" ref-type="bibr">105</xref>). The B.1.617 variants doubled the risk of hospitalizations compared to the B.1.1.7 variant, and patients infected with B.1.617 had severe disease outcomes and higher in-hospital morality rates (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>). Vaccine efficacy and neutralizing responses had significant fold-decreases with the introduction of the B.1.617 variant. The B.1.617 variant was the most devastating SARS-CoV-2 variant ever seen, in terms of its ability to replicate, transmit, infect, and inflict pathologies as well as mortality (<xref rid="B107" ref-type="bibr">107</xref>&#8211;<xref rid="B109" ref-type="bibr">109</xref>).</p></sec><sec id="s4_5"><title>B.1.1.529 (Omicron) lineage</title><p>The first reports of B.1.1.529 emerged from South Africa, in November 2021 (<xref rid="B98" ref-type="bibr">98</xref>). Several studies confirmed that the B.1.1.529 spike protein had 32 mutations, including amino acid substitutions, insertions, and deletions (A67V, &#916;69-70, T95I, &#916;142-144, Y145D, &#916;211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F) (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>) (<xref rid="B98" ref-type="bibr">98</xref>). The overwhelming number of mutations were predicted to result in the most virulent, infectious, transmissive, and pathogenic virus yet. However, the acquisition of these mutations reduced disease severity clinically (<xref rid="B110" ref-type="bibr">110</xref>). Hui et&#160;al. found that the B.1.1.529 variants had a lower replication rate compared to other SARS-CoV-2 variants (<xref rid="B110" ref-type="bibr">110</xref>). The paper suggests the reduced replication efficiency as a potential explanation for reduced disease severity in patients infected with B.1.1.529. In South Africa, hospital admissions lowered by 29%, compared to the first wave in 2020, highlighting less severe disease outcomes associated with the B.1.1.529 variant (<xref rid="B111" ref-type="bibr">111</xref>). The U.S. Food and Drug Administration and Public Health Ontario reported that Antigen Diagnostic Tests were less sensitive in detecting the B.1.1.529 variant as more false negative outcomes were registered (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>). Further analysis revealed a 9-nucleotide deletion resulting in failure to detect the SARS-CoV-2 B.1.1.529 variant (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>). According to Ontario&#8217;s Risk Assessment report, the B.1.1.529 variant dominated COVID cases with numbers increasing from 838 to 14449 within a two-week period in December 2021 (<xref rid="B112" ref-type="bibr">112</xref>). In South Africa, B.1.1.529 case numbers increased by 2.5 folds within November 2021 (<xref rid="B75" ref-type="bibr">75</xref>). The B.1.1.529 variants and its closely related sub-variants, BA.1 and BA.2, were reported to have alarming rates of transmission, making it a major concern for public health (<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>).</p></sec></sec><sec id="s5"><title>1st generation COVID-19 vaccines-induced immunity against SARS-CoV-2 VOCs</title><p>The timely development of the current 1<sup>st</sup> generation COVID-19 vaccines, including Pfizer/BioNTech (BNT162b2), Moderna (mRNA-1273), AstraZeneca (ChAdOx1nCov-19), and Johnson and Johnson (Ad26.COV2-S), have significantly reduced case numbers, hospitalizations, and deaths related to COVID-19 (<xref rid="B117" ref-type="bibr">117</xref>). These vaccines have a common spike-based design from the wild-type, Wuhan-Hu-1 isolate, which is intended to elicit neutralizing antibody responses against the SARS-CoV-2 spike protein (<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>). Antibody responses against the spike protein has been associated with protection against COVID-19 infections. However, SARS-CoV-2 variants, from alpha to omicron, are consistently mutating the S protein, resulting in the reduction of vaccine efficacy rates of these vaccines as the neutralizing antibodies are unable to recognize novel S protein alterations. Therefore, immunity against spike can be neutralizing, but cannot be sustained for long-term protection against heterologous SARS-CoV-2 S proteins and future variants. Interestingly, all four vaccines have a similar antigenic composition, but the immunity generated from these vaccines have different capacities of inducing heterologous immunity. The 1<sup>st</sup> generation vaccines are an example of how immunizations with the wild-type SARS-CoV-2 S protein elicits varying degrees of protection against novel variants of SARS-CoV-2, which have different compositions of spike mutations compared to the Wuhan-Hu-1 strain (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Summary of reported vaccine effectiveness, vaccine efficacies against hospitalizations/COVID-19 disease, and antibody neutralization of 1<sup>st</sup> generation COVID-19 vaccine against five variants of concerns: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617), and omicron (B.1.1.529) variants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="2" align="left" rowspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Alpha (B.1.1.7) Variant</th><th valign="top" colspan="2" align="center" rowspan="1">Beta (B.1.351) Variant</th><th valign="top" colspan="2" align="center" rowspan="1">Gamma (P.1) Variant</th><th valign="top" align="center" rowspan="1" colspan="1">Delta (B.1.617) Variant</th><th valign="top" align="center" rowspan="1" colspan="1">Omicron (B.1.1.529) Variant</th></tr></thead><tbody><tr><td valign="top" rowspan="3" align="left" colspan="1">AstraZeneca<break/>(ChAdOx1nCov-19)</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Effectiveness</td><td valign="top" align="left" rowspan="1" colspan="1">70.4%<sup>127-129</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">&#8211;</td><td valign="top" colspan="2" align="left" rowspan="1">77.9%<sup>130</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">67.0%<sup>131</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">34-37%<sup>133,134</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Efficacy Against Hospitalization/COVID-19 Disease</td><td valign="top" align="left" rowspan="1" colspan="1">Protective (100%)<sup>128,129</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">No Protection<sup>126</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">Protective (87.6%)<sup>130</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">Protective<sup>131</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antibody Neutralization</td><td valign="top" align="left" rowspan="1" colspan="1">Preserved<sup>126</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">No Neutralization Capacity<sup>81,126</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">9-Folds Reduction<sup>133,134</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" rowspan="3" align="left" colspan="1">Johnson and Johnson<break/>(Ad26.COV2-S)</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Effectiveness</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" colspan="2" align="left" rowspan="1">&#8211;</td><td valign="top" colspan="2" align="left" rowspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">76.0%<sup>145</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Efficacy Against Hospitalization/COVID-19 Disease</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" colspan="2" align="left" rowspan="1">&#8211;</td><td valign="top" colspan="2" align="left" rowspan="1">73.1-81.7%<sup>138</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">81.0%<sup>145</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">63.0%<sup>156</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antibody Neutralization</td><td valign="top" align="left" rowspan="1" colspan="1">Preserved<sup>141-144</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">3.6-Fold Reduction<sup>140</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">3.4-Fold Reduction<sup>140</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">1.6-Fold Reduction</td><td valign="top" align="left" rowspan="1" colspan="1">No Neutralization Capacity<sup>146-149</sup>
</td></tr><tr><td valign="top" rowspan="3" align="left" colspan="1">Moderna<break/>(mRNA-1273)</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Effectiveness</td><td valign="top" align="left" rowspan="1" colspan="1">100%<sup>161,162</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">96.4%<sup>161,162</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">86.7%<sup>161,162</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">44.0%<sup>168,169</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Efficacy Against Hospitalization/COVID-19 Disease</td><td valign="top" align="left" rowspan="1" colspan="1">Protective<sup>160-163</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">Protective<sup>160-163</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">Protective<sup>160-163</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">Protective<sup>160-163</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">Reduced Protection<sup>160-163</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antibody Neutralization</td><td valign="top" align="left" rowspan="1" colspan="1">1.2-Fold Reduction<sup>171</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">8.4-Fold Reduction<sup>171</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">3.2-Fold Reduction<sup>171</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">3.3-Fold Reduction<sup>171</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" rowspan="3" align="left" colspan="1">Pfizer/BioNTech<break/>(BNT162b2)</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Effectiveness</td><td valign="top" align="left" rowspan="1" colspan="1">93.7%<sup>173-176</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">75.0%<sup>173-176</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">88.0%<sup>173-176</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">70%<sup>173-176</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vaccine Efficacy Against Hospitalization/COVID-19 Disease</td><td valign="top" colspan="7" align="left" rowspan="1">95% Effectiveness at Protecting Against COVID-19 Disease<sup>173</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antibody Neutralization</td><td valign="top" colspan="2" align="left" rowspan="1">2.6-Fold Reduction<sup>177,178</sup>
</td><td valign="top" colspan="2" align="left" rowspan="1">4.9-Fold Reduction<sup>177,178</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">5.8-Fold Reduction<sup>177,178</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">41-Fold Reduction<sup>177,178</sup>
</td></tr></tbody></table><table-wrap-foot><fn><p>The dash (-) is placed where data was not available for the defined parameter.</p></fn></table-wrap-foot></table-wrap><sec id="s5_1"><title>Oxford-AstraZeneca (ChAdOx1nCov-19) vaccine</title><p>The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1nCov-19) is a non-replicating viral vector vaccine (<xref rid="B119" ref-type="bibr">119</xref>). It utilizes a chimpanzee adenovirus vector encoding the wild-type SARS-CoV-2 S protein. The two-dose regimen of ChAdOx1nCov-19 induces a robust immune response composed of IgG<sub>1</sub>/IgG<sub>3</sub> antibodies and T cell responses directed at Wuhan-Hu-1 spike protein. It also activates a T<sub>H</sub>1 response <italic toggle="yes">via</italic> CD4<sup>+</sup> T cell secretion of IFN-&#947;/TNF-&#945; (<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B119" ref-type="bibr">119</xref>). The immunity induced by ChAdOx1nCov-19 has been targeted towards the RBD as both antibody and T cells epitopes are specific for that region of spike. ChAdOx1nCov-19 vaccination trials conducted in the UK (11 636 participants) reported an overall vaccine efficacy rate of 70.4% (95.8% CI, 54.8-80.6) (<xref rid="B120" ref-type="bibr">120</xref>&#8211;<xref rid="B122" ref-type="bibr">122</xref>). Furthermore, 21 days after the 1<sup>st</sup> dose, there were zero hospitalizations reported within the vaccinated group compared to 15 hospitalizations in the control group (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). Their analysis showed that the two-dose regimen of ChAdOx1nCov-19 requires more than 14 days after the 2<sup>nd</sup> dose to effectively protect against COVID-19 disease (<xref rid="B122" ref-type="bibr">122</xref>). ELISA-based virus neutralization assays revealed that the antibody response induced by ChAdOx1nCov-19 has preserved its effectiveness in protecting against severe disease outcomes of B.1.1.7 (Alpha) variants, however a marginal reduction was observed (<xref rid="B119" ref-type="bibr">119</xref>).</p><p>Following the B.1.1.7 (Alpha) wave, the B.1.351 (Beta) variant dominated the COVID-19 landscape in many countries around the world. Vaccine efficacy studies on ChAdOx1nCov-19 reported ineffectiveness against B.1.351 as antibody neutralizing ability was reduced against the D614G spike mutation (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B119" ref-type="bibr">119</xref>). Thus, the humoral response against SARS-CoV-2 is highly compromised by viral mutation. A single amino acid change has the ability make an antibody response ineffective as the study reported vaccine efficacies dropped to 10.4% against mild-to-moderate disease caused by B.1.351 variants. These results caused several countries to halt rollout plans for the AstraZeneca vaccine (<xref rid="B75" ref-type="bibr">75</xref>). A more positive experience occurred in Brazil where a two-dose regimen of AstraZeneca was implemented during the epidemic with the P.1 (Gamma) variant. Reports out of Brazil indicated that one dose of ChAdOx1nCov-19 had mitigating effects against COVID-19 as hospitalizations and deaths decreased by 55.1% (95% CI, 46.6-62.2) and 61.8% (95% CI, 48.9-71.4), respectively (<xref rid="B123" ref-type="bibr">123</xref>). Moreover, after two doses of ChAdOx1nCov-19, administered three months apart, the effectiveness against the P.1 variant was 77.9%, and hospitalizations and deaths were reduced to 87.6% (95% CI, 78.2-92.9) and 93.6% (95% CI, 81.9-97.7), respectively (<xref rid="B123" ref-type="bibr">123</xref>). Similarly, the AstraZeneca vaccine has shown effectiveness in reducing hospitalizations and risk of COVID infections against the B.1.617 (Delta) variant (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B124" ref-type="bibr">124</xref>). However, the vaccine effectiveness of ChAdOx1nCov-19 against B.1.617 is diminishing when compared to the B.1.1.7 (Alpha) variant (<xref rid="B124" ref-type="bibr">124</xref>&#8211;<xref rid="B126" ref-type="bibr">126</xref>). The effectiveness of the two-dose regimen was 74.5% (95% CI, 68.4 to 79.4) against the B.1.1.7 variant and 67.0% (95% CI, 61.3 to 71.8) against the B.1.617 variant (<xref rid="B124" ref-type="bibr">124</xref>). Compared to the Wuhan-Hu-1 SARS-CoV-2 strain, sera from AstraZeneca-vaccinated individuals have reduced neutralizing ability against B.1.617 variant by 9-fold (<xref rid="B125" ref-type="bibr">125</xref>). The overall trend observed as novel SARS-CoV-2 variants emerge is that the AstraZeneca vaccine is becoming less effective. Furthermore, vaccine effectiveness has significantly been compromised with the emergence of the B.1.1.529 (Omicron) variant (<xref rid="B75" ref-type="bibr">75</xref>). Andrews et&#160;al. found there was no protection after 15 weeks of completing the two-dose regimen of ChAdOx1nCov-19, and vaccine efficacy dropped to 34-37%, against the B.1.1.529 variant (<xref rid="B127" ref-type="bibr">127</xref>). The study also showed that AstraZeneca recipients, with a Pfizer (BNT162b2) booster restored effectiveness against the B.1.1.529 infections to 92.6% (<xref rid="B127" ref-type="bibr">127</xref>). Taken together, it appears that there are cross-reactive mechanisms induced by ChAdOx1nCov-19 that promote cross-protection against the B.1.1.7 and P.1 variants. Cross-reactive mechanisms are critical and desirable for heterologous immunity as these mechanisms will orchestrate and dictate the protective ability against SARS-CoV-2 variants and heterologous pathogens (<xref rid="B117" ref-type="bibr">117</xref>). The ChAdOx1nCov-19 vaccine is effective at inducing heterologous immunity as immune responses are providing a certain degree of effectiveness against B.1.1.7 (Alpha), P.1 (Gamma), and even B.1.617 (Delta) variants (<xref rid="B117" ref-type="bibr">117</xref>&#8211;<xref rid="B127" ref-type="bibr">127</xref>). In contrast, it is evident that ChAdOx1nCov-19 induced immunity was not cross-protective towards the B.1.1.529 (Omicron) variant (<xref rid="B117" ref-type="bibr">117</xref>&#8211;<xref rid="B127" ref-type="bibr">127</xref>).</p></sec><sec id="s5_2"><title>Johnson &amp; Johnson (Ad26.COV2-S) vaccine</title><p>The Johnson &amp; Johnson (J&amp;J) vaccine is a non-replicating viral vector vaccine composed of a human adenovirus type 26 incorporating a full-length wild type S protein (<xref rid="B128" ref-type="bibr">128</xref>). J&amp;J vaccine, Ad26.CoV2-S, is a single-dose regimen that generates a robust antibody response targeting the spike protein and RBD (<xref rid="B129" ref-type="bibr">129</xref>). Spike and RBD-specific IgA<sub>1</sub>, IgA<sub>2</sub>, IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, IgG<sub>4</sub>, and IgM antibodies were generated from Ad26.CoV2-S and found to cross-react with SARS-CoV-1 S protein and other human coronaviruses such as CoV-229E, CoV-HKU1, CoV-NL63 and CoV-OC43, <italic toggle="yes">in vitro</italic> (<xref rid="B129" ref-type="bibr">129</xref>). The CoV1001 Phase I-IIa clinical trial reported humoral and cellular responses against B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) variants in Ad26.CoV2-S vaccinated individuals (<xref rid="B129" ref-type="bibr">129</xref>&#8211;<xref rid="B135" ref-type="bibr">135</xref>). Regarding the B.1.1.7 (Alpha) variant, sera from Ad26.CoV2-S recipients were tested for their neutralizing activity with a pseudovirus inhibition neutralization assay, reporting that Ad26.CoV2-S has significant neutralization ability against B.1.1.7 (<xref rid="B132" ref-type="bibr">132</xref>&#8211;<xref rid="B135" ref-type="bibr">135</xref>). They found that antibody-dependent cellular phagocytosis, complement pathways and natural killer cells were activated against B.1.351 infections (<xref rid="B131" ref-type="bibr">131</xref>). In contrast, pseudovirus neutralization assay results indicated that the effectiveness of neutralizing antibody responses were lowered 5.0-fold and 3.3-fold against B.1.351 and P.1 variants, respectively (<xref rid="B131" ref-type="bibr">131</xref>). Although protection against infection was reduced significantly, a vaccine safety study conducted in South Africa reported a single dose of Ad26.CoV2-S protected against severe-to-critical disease outcomes, reducing COVID-19-related hospitalizations and deaths (<xref rid="B130" ref-type="bibr">130</xref>). The study reported a vaccine efficacy of 73.1% and 81.7% against moderate-to-critical COVID-19, on days 14 and 28 post-vaccination, respectively (<xref rid="B130" ref-type="bibr">130</xref>). The antibody response induced by Ad26.CoV2-S has cross-variant capabilities that recognized the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) variants, and clinically exhibited protection against VOCs, despite waning neutralization ability. Ad26.CoV2-S vaccination induced multiple antibody isotypes, including IgA, IgG, and IgM, which allows antibody protection at many sites of the body, including mucosal barriers, blood, lymphatic fluids, and other extracellular fluids. Inducing a diversified antibody response may be linked to better protective outcomes against SARS-CoV-2 variants. Collectively, an IgA/IgG/IgM response increases the coverage of the humoral immunity to multiple locations around the body and broadens the function of the antibody response, compared to an antibody response mediated by a single antibody isotype as seen with ChAdOx1nCov-19 (<xref rid="B131" ref-type="bibr">131</xref>). Notably, IgA antibodies play an important role in fighting infections in the respiratory tract and serve to defend against cell entry of respiratory viruses. Specifically with SARS-CoV-2 infections, a robust IgA response can potentially have neutralizing effects as the virus can be eliminated before reaching the respiratory epithelia and binding to ACE2. Early indicators of a robust IgA response and increased sampling of antibodies at the mucosal barriers may serve as a strong indicator of protection against SARS-CoV-2 infections. In addition to a diversified humoral response, non-neutralizing CD4<sup>+</sup>/CD8<sup>+</sup> T effector and central memory cells were found to response to SARS-CoV-2 variants in vaccinated individuals. These memory populations may contribute to the protection against disease severity, but the role of these populations is still unclear (<xref rid="B131" ref-type="bibr">131</xref>).</p><p>Following the B.1.351 and P.1 variants, the B.1.617 (Delta) variant dominated the United States. A cohort study with 422 034 Ad26.CoV2-S vaccinated individuals reported vaccine efficacy rates of 76% against B.1.617 (Delta) variant infections, and 81% against COVID-19 related hospitalizations (<xref rid="B136" ref-type="bibr">136</xref>). These vaccine efficacies were maintained for 180 days after vaccination. Additionally, a neutralization study found that sera from Ad26.CoV2-S recipients was reduced 1.6-fold against the B.1.617 variant, while the most noteworthy reduction was observed against B.1.351(3.6-fold) and P.1(3.4-fold) variants (<xref rid="B137" ref-type="bibr">137</xref>). Mandy et&#160;al. suggests this lower neutralization by Ad26.CoV2-S-vaccinated sera may be associated with mutational differences in the RBD between variants. The RBD mutations associated with immune evasion, K417T,&#160;N501Y and&#160;E484K, have been identified in the B.1.351 and P.1 variants; whereas the B.1.617 variant has acquired mutations at, L452R and T478K, associated with infectivity (<xref rid="B137" ref-type="bibr">137</xref>). A repetitive theme has been observed with S-based antibody responses induced by vaccines: as novel mutations are acquired by variants, the neutralization capability declines. Mechanistically, antibodies recognize epitopes on pathogens to provide immunity against a given pathogen. However, the tendency of pathogens to evolve and mutate alters these epitopes to the point where antibodies are unable to recognize their targets, leading to an unprotective humoral response. Therefore, a vaccine that induces heterologous immunity cannot only depend on spike- and RBD-specific neutralizing antibodies to provide long term and cross-variant immunity. As novel SARS-CoV-2 variants are emerging, more mutations accumulate in the S protein and the antibody responses are expected to weaken. Many studies have reported sera from Ad26.CoV2-S recipients display a substantial fold decrease or no neutralization capability against the B.1.1.529 (Omicron) variant (<xref rid="B138" ref-type="bibr">138</xref>&#8211;<xref rid="B140" ref-type="bibr">140</xref>). With over 30 mutations in the spike, antibody responses have proven to be insufficient at protecting against Omicron infections. This shifted the focus towards looking at other immune parameters conferring vaccine induced immunity against the Omicron variant. A study with macaques immunized with Ad26.CoV2-S vaccine found the presence of cross-reactive CD8<sup>+</sup> T cell responses against the Omicron variant (<xref rid="B141" ref-type="bibr">141</xref>&#8211;<xref rid="B143" ref-type="bibr">143</xref>). Further evaluation of the vaccinated group found that immunologic profiles with moderate omicron-specific neutralizing antibody (NAbs) titres and negligible CD8<sup>+</sup> T cell responses, and low-to-moderate Omicron NAbs titres and low CD8<sup>+</sup> T cell responses fail to establish viral control in the upper respiratory tract. Meanwhile, macaques with low NAbs titres and high CD8<sup>+</sup> T cell responses, and high NAbs titre and low CD8<sup>+</sup> T cell response, established virological control upon SARS-CoV-2 challenge. The paper suggests that CD8<sup>+</sup> T cells responses play an important role in viral protection and control against SARS-CoV-2 variants. Other studies comparing cellular responses among COVID-19 vaccines have reported Ad26.CoV2-S recipients with a sustainable CD4<sup>+</sup>/CD8<sup>+</sup> T cell response at 8 months post-vaccination. The median CD8<sup>+</sup> T cell counts for Ad26.CoV2-S recipients (0.12%) were significantly higher compared to BNT162b2 (0.016%) and mRNA-1273 recipients (0.017%) (<xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B145" ref-type="bibr">145</xref>). All in all, the waning efficacy rates of Ad26.CoV2-S vaccine against the B.1.1.529 (Omicron) variants highlighted the susceptibilities of the vaccine-induced humoral responses and emphasized the importance of cellular responses.</p><p>Evidently, Ad26.CoV2-S recipients were not protected from Omicron infections, therefore, research into homologous (same as the initial vaccine) and heterologous (different from the initial vaccine) booster vaccines were explored to re-establish the lost immunity. It was determined that both, heterologous and homologous boosting regimens were safe and effective at restoring immunity against the Omicron variant (<xref rid="B145" ref-type="bibr">145</xref>). A primary Ad26.CoV2-S vaccination, followed by Pfizer vaccine booster shot increased NAbs titers by 6- to 73-fold, compared to a homologous booster shot which increase titers by 4- to 20-fold (<xref rid="B146" ref-type="bibr">146</xref>). Spike-specific CD8<sup>+</sup> T cell counts were significantly increased with the heterologous boosting regimen, whereas homologous boosting induced a more long-lasting spike-specific CD8<sup>+</sup> T cell response. In South Africa, 500 000 health care workers were given a homologous Ad26.CoV2-S boosting regimen to follow and found vaccine efficacy for hospitalization increased from 63% to 84% (<xref rid="B147" ref-type="bibr">147</xref>). Another clinical trial among health care workers, the SWITCH Trial, compared the homologous Ad26.CoV2-S regimen with a heterologous mRNA-vaccine based regimen, and found the strongest response occurred from the mRNA-based boosting regimen (<xref rid="B145" ref-type="bibr">145</xref>). Heterologous mRNA-based boosters generate a higher NAb titer compared to the homologous Ad26.CoV2-S regimen (<xref rid="B145" ref-type="bibr">145</xref>). Additionally, all recipients of a booster shot demonstrated spike-specific IFN-&#947;<sup>+</sup> T cell responses. Moreover, the mRNA booster (mRNA-1273: 91.7%; BNT162b2: 91.5%) has a cellular recall response compared to the Ad26.CoV2-S (72.7%) booster shot (<xref rid="B145" ref-type="bibr">145</xref>). Data on vaccine efficacy against infection, transmission and severe disease are not available, but are predicted to increase based on the humoral and cellular response data.</p></sec><sec id="s5_3"><title>Moderna (mRNA-1273) vaccine</title><p>The Moderna, mRNA-1273, vaccine is an mRNA lipid nanoparticle encoding the wild-type SARS-CoV-2 spike protein with a transmembrane anchor and cleavage site (<xref rid="B148" ref-type="bibr">148</xref>). It is an FDA-approved vaccine for all ages, consisting of a two-dose regimen, 28 days apart. Moderna (mRNA-1273) elicits a strong CD4<sup>+</sup> T cell response and neutralizing antibody titre against the RBD (<xref rid="B149" ref-type="bibr">149</xref>). An evaluation of the mRNA vaccine-induced responses by Bezawit et&#160;al. revealed CD4<sup>+</sup> T cells with cross-variant and cross-species reactivity as they recognize the B.1.1.7/B.1.351 S-protein as effectively as the wild-type SARS-CoV-2 and heterologous HCoV-HL63 S-protein (<xref rid="B150" ref-type="bibr">150</xref>). In addition, the antibody response had cross-reactive properties towards B.1.1.7/B.1.351 variants, leading to a robust NAb titer. The mRNA-1273-induced immunity was found effective as vaccine efficacies against B.1.1.7, B.1.351 and B.1.617 infections, after two doses of mRNA-1273, were 100%, 96.4% and 86.7%, respectively (<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>). Moreover, mRNA-1273 recipients were protected from severe COVID-19 outcomes and hospitalizations against the B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617 (Delta) variants (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B150" ref-type="bibr">150</xref>&#8211;<xref rid="B152" ref-type="bibr">152</xref>). The emergence of the B.1.1.529 (Omicron) variant had negative implications for the Moderna vaccine. There was a significant reduction in effectiveness of the vaccine in protecting against infection, but protection against severe disease was still observed (<xref rid="B153" ref-type="bibr">153</xref>&#8211;<xref rid="B156" ref-type="bibr">156</xref>). Serum samples from mRNA-1273 recipients showed 41-to-84-fold reduction in neutralization ability, and vaccine efficacy declined against the B.1.1.529 (Omicron) infections to 44.0% (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>). With the marked reduction in protection against infection, an mRNA-1273 booster shot was encouraged. The administration of an mRNA-1273 booster restored vaccine efficacies against hospitalization and disease outcomes of COVID-19. Unfortunately, the efficacy of the booster shot against Omicron infections dropped from 71.6% to 47.4%, after 60 days (<xref rid="B157" ref-type="bibr">157</xref>). Research shows that the booster shots may be a temporary measure to mitigate the infectivity associated with emerging SARS-CoV-2 variants as the human population remains highly susceptible to SARS-CoV-2 infections.</p><p>The mRNA-based vaccines have proven to generate a more robust and durable memory response compared to the other COVID-19 vaccine types. The mRNA-1273 and BNT162b2, have been shown to induce spike- and RBD-specific memory B cells that cross-react with B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617 (Delta) variants and generated functional neutralizing antibodies (<xref rid="B159" ref-type="bibr">159</xref>). The study found that more than 50% of memory B cells cross-reacted with the three VOC (<xref rid="B159" ref-type="bibr">159</xref>). This cross-variant humoral response generated from the mRNA vaccines has shown to be effective as vaccine efficacy against the Alpha, Beta and Delta infections remains high (<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B159" ref-type="bibr">159</xref>). In terms of heterologous immunity, this is an ideal humoral response as it confers specificity against spike and RBD targets, establishes memory, cross-reactivity, and protects against infection. Regarding a sustainable, cross-reactive humoral response, these memory B cells increased in frequency from 3 to 6 months post-vaccination, and variant-binding memory B cells were reported to be more hypermutated compared to wild-type binding memory B cells (<xref rid="B159" ref-type="bibr">159</xref>). However, Choi et&#160;al. found that sera from mRNA-1273 recipients have reductions in neutralizing ability against B.1.351 (Beta), P.1(Gamma) and B.1.617 (Delta) variants, ranging from 2.1- to 8.4-fold (<xref rid="B160" ref-type="bibr">160</xref>). Despite the reduction in neutralizing ability, the mRNA vaccine efficacies against infections have remained intact, whereas protection against SARS-CoV-2 infections dropped with the Ad26.CoV2-S and ChAdOx1nCov-19 vaccines (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B160" ref-type="bibr">160</xref>). Goel et&#160;al. has associated this resilience to the early establishment of CD4<sup>+</sup> T follicular cells, the presence of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> memory T cells 3-to-6 months after vaccination, and rapid recall responses upon re-exposure of antigen (<xref rid="B159" ref-type="bibr">159</xref>). Notably, early CD4<sup>+</sup> T follicular cells have been correlated to antibody production at 6 months post-vaccination, emphasising the role of early cellular responses in long term immunity against SARS-CoV-2. Second, the stabilization and rapid recall of SARS-CoV-2 specific CD4<sup>+</sup> and CD8<sup>+</sup> memory responses has been shown to correlate with long-term humoral immunity. Perhaps, as the antibody responses decline in neutralization ability, CD4<sup>+</sup> T follicular cells and other T memory responses reactivate in germinal centres, and other mechanisms that facilitate memory B cells to undergo somatic hypermutation, produce functional cross-reactive antibodies that also come to play. Interestingly, T follicular cells and other populations influencing germinal centres may play an important role in adapting humoral memory responses against emerging SARS-CoV-2 variants. Moreover, inducing heterologous immunity against SARS-CoV-2 may manifest within these T cell populations that allows the adaptive immune system to repurpose their immune mechanisms to the changing landscape of SARS-CoV-2 variants.</p></sec><sec id="s5_4"><title>Pfizer/BioNTech (BNT162b2) vaccine</title><p>Pfizer/BioNTech manufactured a lipid nanoparticle mRNA vaccine that encodes full-length wild type spike protein (<xref rid="B120" ref-type="bibr">120</xref>). The Pfizer/BioNTech (BNT162b2) vaccine induces a high neutralizing IgG/IgA antibody titre, activates CD4<sup>+</sup>/CD8<sup>+</sup> T cells and memory B cell responses against the S-protein, including the RBD (<xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B161" ref-type="bibr">161</xref>). A two-dose regimen of BNT162b2 has an overall 95% effectiveness at protecting against COVID-19 disease outcomes, and vaccine efficacies against B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617 (Delta), and B.1.1.529 (Omicron) variants were 93.7%, 75.0%, 88.0%, and 70%, respectively (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>). Serum samples from BNT162b2 recipients showed neutralization ability declining as novel variants emerged. Antibody neutralization responses were reduced by 2.6-fold, 4.9-fold, 5.8-fold, and 41-fold against B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617 (Delta), and B.1.1.529 (Omicron) (<xref rid="B164" ref-type="bibr">164</xref>, <xref rid="B165" ref-type="bibr">165</xref>). The Pfizer vaccine has been shown to be effective until the emergence of the B.1.1.529 (Omicron) variant when the vaccine-induced immunity against infection was significantly compromised (<xref rid="B166" ref-type="bibr">166</xref>). Subsequently, protection against hospitalizations and disease have also been negatively impacted. Fortunately, many studies have reported that a booster dose restored the neutralization ability of recipient-sera against the B.1.1.529 (Omicron) variant (<xref rid="B167" ref-type="bibr">167</xref>&#8211;<xref rid="B170" ref-type="bibr">170</xref>). The first dose of BNT162b2 generated an early S<sub>2</sub>-specific IgA<sup>+</sup> plasmablast response, which is an early indicator of IgA-secretion (<xref rid="B167" ref-type="bibr">167</xref>). Then development of an IgG<sup>+</sup> memory B cell response, targeting the S<sub>1</sub> subunit of the spike protein, was observed three-weeks after the first shot (<xref rid="B167" ref-type="bibr">167</xref>). The second dose served to boost the established humoral responses and produce functional NAbs against SARS-CoV-2 and its variants (<xref rid="B167" ref-type="bibr">167</xref>). Furthermore, one week after the second dose, the antibody response efficiently blocked viral entry of the B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617 (Delta) variants (<xref rid="B168" ref-type="bibr">168</xref>). However, the antibody titers and entry inhibition proficiencies were reported to decline at 3- and 6-months after the second dose (<xref rid="B168" ref-type="bibr">168</xref>). The BNT162b2 vaccine-induced humoral response was robust and effective in the early stages, but from one week onwards, the humoral response began to wane.</p><p>The success of mRNA vaccines against SARS-CoV-2 has been attributed to its multi-dimensional approach to priming immune mechanisms to mitigate the pathologies, infections, hospitalizations, and deaths related to COVID-19. The role of the antibody response is to neutralize extracellular viruses entering the host from the environment or prevent newly released virions from infecting additional host cells. When the antibody responses weaken, the virus can infect host cells and it is the responsibility of CD8<sup>+</sup> T cells to eliminate viruses intracellularly. In addition to blocking cell attachment and entry, antibodies can also lead to killing of virus infected cells <italic toggle="yes">via</italic> ADCC (antibody dependent cellular cytotoxicity) and CDCC (complement dependent cellular cytotoxicity). The CD4<sup>+</sup> T cell response orchestrates cellular mechanisms to protect against infectious agents such as SARS-CoV-2, by providing B and T cell help, generating memory, and balancing T<sub>H</sub>1 vs T<sub>H</sub>2 responses (<xref rid="B169" ref-type="bibr">169</xref>). The T cell immunity elicited by the BNT162b2 vaccine shows longevity and protection against SARS-CoV-2 variants (<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B171" ref-type="bibr">171</xref>). Guerrera et&#160;al. found spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T memory cells, two-weeks, and 6-months after vaccination (<xref rid="B171" ref-type="bibr">171</xref>). These CD4<sup>+</sup>/CD8<sup>+</sup> T memory cells were poly-functional, inducing T<sub>H</sub>1 cytokines (IFN-&#947; and IL-2), generating S-specific central memory (T<sub>CM</sub>) and effector memory (T<sub>EM</sub>) populations, and activating T stem cell memory (T<sub>SCM</sub>) (<xref rid="B171" ref-type="bibr">171</xref>). The T<sub>SCM</sub> populations were stable and deemed a predictor for activated spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells at 6-months post-vaccination (<xref rid="B171" ref-type="bibr">171</xref>). T<sub>SCM</sub> cells have self-renewal ability and function to replenish memory and effector subsets populations (<xref rid="B172" ref-type="bibr">172</xref>). It has been theorized that immunological memory and decade-lasting protective immunity stems from T<sub>SCM</sub> populations differentiating into antigen-specific memory T cells subsets, upon re-exposure of antigen (<xref rid="B172" ref-type="bibr">172</xref>&#8211;<xref rid="B175" ref-type="bibr">175</xref>). Guerrera et&#160;al. have emphasized the stabilization and rapid recall ability of T<sub>SCM</sub> populations as a signature for a sustainable cellular response (<xref rid="B171" ref-type="bibr">171</xref>). Another study examined memory responses associated with the Pfizer booster. They reported a strong IFN-&#947;<sup>+</sup> or IL-2<sup>+</sup> response in CD4<sup>+</sup>/CD8<sup>+</sup> T cells, and early differentiation of SARS-CoV-2 specific CD8<sup>+</sup> T cells into T<sub>EM</sub> populations, which accounted for 0.02-2.92% of circulating CD8<sup>+</sup> T cells (<xref rid="B169" ref-type="bibr">169</xref>). These CD8<sup>+</sup> T cells responded to epitopes that were frequently presented by MHC alleles and conserved across SARS-CoV-2 variants, which allowed the memory T cells to develop cross-variant specificity (<xref rid="B169" ref-type="bibr">169</xref>). It is evident that successful COVID-19 vaccines have an intricate induction of T cell pathways and mechanisms that are diverse in their functionality and ability to recognize variants. These attributes observed in the mRNA vaccines have led to protection against B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617 (Delta), and B.1.1.529 (Omicron) variants, despite waning antibody responses over time post-vaccination.</p></sec></sec><sec id="s6"><title>COVID-19 vaccines in pipeline</title><p>The emergence of the B.1.1.529 (Omicron) variant, paralleled with the significant decline in efficacies of the 1<sup>st</sup> generation COVID-19 vaccines to this variant, has mobilized attention to the future composition of COVID-19 vaccines. Currently, there are 153 vaccine candidates in clinical development, of which six candidates have shown significant protection against SARS-CoV-2 in later-phase trials (<xref rid="B176" ref-type="bibr">176</xref>).</p><p>(1) Covaxin (BBV152) has been developed by Bharat Biotech, in cooperation with the Indian Council of Medical Research, National Institute of Virology (<xref rid="B176" ref-type="bibr">176</xref>&#8211;<xref rid="B178" ref-type="bibr">178</xref>). It is a whole inactivated virion of SARS-CoV-2 tagged with a Toll-Like Receptor (TLR) -7/-8 agonist molecule (IMDG), and Alhydroxiquim-II adjuvant (<xref rid="B178" ref-type="bibr">178</xref>). In Phase III clinical trials with 25 798 participants, Covaxin had a vaccine efficacy of 77.8% against mild-to-moderate COVID-19, 93.4% against severe COVID-19, and 65.2% against the Delta variant (<xref rid="B177" ref-type="bibr">177</xref>, <xref rid="B178" ref-type="bibr">178</xref>). This vaccine is approved for emergency use in 16 countries and currently under review for approval by Health Canada and FDA. (2) The GBP510 vaccine is developed by SK Bioscience and GlaxoSmithKline (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>). It is an adjuvanted self-formulating nanoparticle vaccine targeting the RBD of SARS-CoV-2. Interim Phase I/II results indicated a 100% seroconversion rate and a strong neutralizing antibody response that was 5-8 times higher than convalescent sera (<xref rid="B178" ref-type="bibr">178</xref>). The Phase III clinical trial results have been yet to be posted (<xref rid="B179" ref-type="bibr">179</xref>). (3) INO-4800 developed by Inovio Pharmaceuticals, is a prophylactic DNA vaccine targeting the SARS-CoV-2 S-protein (<xref rid="B176" ref-type="bibr">176</xref>, <xref rid="B178" ref-type="bibr">178</xref>). The vaccine has been reported to induce a functional antibody and CD4<sup>+</sup>/CD8<sup>+</sup> T cell response against all the VOCs, including the Delta variant (<xref rid="B178" ref-type="bibr">178</xref>). Phase II/II INNOVATE trial are evaluating the INO-4800 vaccine and results are pending. (4) Novavax developed a nanoparticle vaccine consisting of a stable pre-fused, coronavirus S-protein coupled with a Matrix-M adjuvant (<xref rid="B178" ref-type="bibr">178</xref>). In animal models, NVX-CoV2373 showed that a single-dose regimen induced high spike-specific NAbs (<xref rid="B180" ref-type="bibr">180</xref>). Phase III trials reported a vaccine efficacy of 90.4% against mild-to-severe disease, 100% protection against moderate-to-severe disease, and 92.6% efficacy against VOCs (<xref rid="B181" ref-type="bibr">181</xref>). Novavax plans to combine NVX-CoV2373 and an influenza vaccine, NanoFlu, in hopes to address SARS-CoV-2 and influenza virus in the upcoming flu season (<xref rid="B178" ref-type="bibr">178</xref>). A clinical study is underway for evaluating the effectiveness of combining the vaccines. (5) The SCB-2019 (CpG 1018/Alum) vaccine is a stabilized trimeric S-protein with CpG 1018 and Alum adjuvant. Developed by Clover Biopharmaceutical and Dynavax Technologies, the vaccine has shown 100% efficacy against severe disease outcomes and hospitalizations, 84% efficacy against moderate-to-severe disease and overall vaccine efficacies against the B.1.617 (Delta), P.1 (Gamma) and B.1.621 (Mu) variants of 79%, 92% and 59%, respectively (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B182" ref-type="bibr">182</xref>). (6) VBI Vaccines have an enveloped virus-like particle expressing S-protein with an alum adjuvant, called VBI-2902 (<xref rid="B178" ref-type="bibr">178</xref>). Results from Phase I/II trials reported 100% neutralizing Abs titres present in recipients, with 4.3- and 5.0-fold increases in titre after first and second shot, respectively (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B183" ref-type="bibr">183</xref>). With the success of VBI-2902, the company plans on testing out a tri-valent pan-coronavirus vaccine, expressing the SARS-CoV, SARS-CoV-2, and MERS-CoV spike proteins (<xref rid="B183" ref-type="bibr">183</xref>).</p><p>Despite the immunity acquired from natural infections of SARS-CoV-2 and vaccines, breakthrough infections emerge to produce highly transmissible and infectious variants, such as Delta and Omicron, leading to an overall decrease in immunity against SARS-CoV-2. The nature of mRNA viruses and their replicative abilities pose a difficult challenge to eliminate SARS-CoV-2 from the human population. The current COVID-19 vaccines cannot prevent breakthrough infections, and this allows the virus to circulate in humans (and other animals) and periodically lead to outbreaks. There have been three major coronavirus outbreaks in the past 20 years and inevitably the countdown towards the next major outbreak is underway<sup>3</sup>. By limiting vaccine efforts towards SARS-CoV-2, these reoccurring outbreaks cannot be mitigated. The idea of developing a universal (or a pan coronavirus) vaccine would ideally protect against SARS-CoV-2 and all its variants, thus preventing future coronavirus outbreaks. Morens et&#160;al. highlight the five ideal properties of a pan-coronavirus vaccine: 1) preventing SARS-CoV-2 infections and breakthrough infection, 2) inducing long-term mucosal and systemic immunity, 3) preventing community transmission, 4) establishing durable herd immunity, and 5) having universal coverage of <italic toggle="yes">Betacoronaviruses</italic> (<xref rid="B184" ref-type="bibr">184</xref>). To develop a pan-coronavirus vaccine, we must understand the essential protective immune mechanisms and induce these though vaccination.</p></sec><sec id="s7"><title>Correlation to protection</title><p>The term &#8220;correlate of protection (CoP)&#8221; is defined as a statistical measure of the level of protection associated with an immune biomarker. It is the equivalent of predicting vaccine efficacy (<xref rid="B185" ref-type="bibr">185</xref>). CoP establishes a threshold for protection that allows vaccine candidates to be evaluated during clinical trials and selected for approval. However, the primary reason for defining CoP is to identify the immune biomarkers that confer protection against an infectious agent (<xref rid="B186" ref-type="bibr">186</xref>).</p><p>Using <italic toggle="yes">in vitro</italic> neutralization assay data and observed protection from vaccine recipients and convalescent patients, Khoury et&#160;al. created a model that predicted the relationship between the neutralizing antibody response and the degree of protection elicited against SARS-CoV-2 (<xref rid="B187" ref-type="bibr">187</xref>). They determined that the neutralizing antibody responses elicited by vaccines and/or natural infections is an accurate predictor of protection. The model predicts when protection against SARS-CoV-2 infections will decline with time based on neutralization levels dropping, and estimates that booster shots may be required annually to maintain protection against SARS-CoV-2 infections. As mentioned earlier, neutralization capacity positively correlates with protection against SARS-CoV-2 infections (<xref rid="B188" ref-type="bibr">188</xref>). Moreover, the presence of spike-specific IgG antibodies correlates most accurately with neutralization. Clinically, as neutralization capacity drops, the risk of fatal outcomes increases. Dispineri et&#160;al. have outlined the absence of early Nabs to strongly correlate to mortality and delayed viral control (<xref rid="B188" ref-type="bibr">188</xref>). Also, it highlights the presence of NAbs being more important than the magnitude of the NAb titres, in relation to protection (<xref rid="B188" ref-type="bibr">188</xref>). Contrary to general belief, higher magnitude of Nabs has been inversely correlated to disease outcomes. Hospitalized patients with severe COVID-19 have a higher NAb titre compared to mild diseased and asymptomatic patients whose NAb titres are undetectable 50% of the time (<xref rid="B189" ref-type="bibr">189</xref>). Consistent with many papers, Trinit&#233; et&#160;al. reported the magnitude of the NAb titre significantly worsens COVID-19 disease outcomes (<xref rid="B189" ref-type="bibr">189</xref>&#8211;<xref rid="B191" ref-type="bibr">191</xref>). Lafon et&#160;al. analyzed the humoral and cellular responses between mild and severe diseased patients (<xref rid="B192" ref-type="bibr">192</xref>). They found C3a and C5a levels were higher in severe-to-critical diseased patients resulting in elevated anaphylaxis. Elevated NAb titre associated with severe disease leads to large numbers of antigen-antibody complexes to form and trigger the complement cascade (<xref rid="B192" ref-type="bibr">192</xref>). Furthermore, the study showed that CD8<sup>+</sup> T cell responses were associated with low anaphylatoxin level, which were in turn correlated with milder infections (<xref rid="B192" ref-type="bibr">192</xref>). Many vaccine studies report the association of protection from disease outcomes to the function of cellular mechanisms. These reports suggest that cellular responses somehow prevent the exacerbation of the NAb response in mild COVID-19 disease, compared to severe COVID-19 disease. In other words, there is a protective role for cellular immunity in COVID-19 infections and disease outcomes.</p><p>Cellular immune markers are known to contribute to protection against SARS-CoV-2, but there are very few papers that statistically prove the relationship between a cellular marker and its correlation to protection. In rhesus macaques, it was observed that the depletion of CD8<sup>+</sup> T cells decreased protection against re-infection of SARS-CoV-2, suggesting a role for cellular immunity in protection (<xref rid="B193" ref-type="bibr">193</xref>). A study on a novel SARS-CoV-2 spike protein ferritin nanoparticle (SpFN) vaccine found that an early CD4<sup>+</sup> T helper cell response (expressing type 1 cytokines such as IFN-&#947;, TNF-&#945; and IL-2), CD4<sup>+</sup> follicular T cells expressing IL-22, and an NAb response all conferred protection against SARS-CoV-1, and SARS-CoV-2 and its variants (<xref rid="B194" ref-type="bibr">194</xref>). The SpFN-induced NAbs were 50% less cross-reactive against SARS-CoV-1, compared to SARS-CoV-2, however protection was maintained. Therefore, the study suggested that CD4<sup>+</sup> T cell populations contributed to the protection observed against SARS-CoV-1 (<xref rid="B194" ref-type="bibr">194</xref>). Furthermore, looking into comparative studies of recovered COVID-19 patients with mild or severe disease states can provide insight into possible markers that contribute to disease control. Patients with mild disease had a higher proportion of SARS-CoV-2 specific CD8<sup>+</sup> T cells (<xref rid="B195" ref-type="bibr">195</xref>). In a similar study, SARS-CoV-2 specific CD4<sup>+</sup> T cells that associated with mild disease were characterized by low proliferation ability, enhanced HLA-DR expression, and limited cytokines production (<xref rid="B196" ref-type="bibr">196</xref>). Moreover, in mild disease patients, there was a higher proportion of M-/N-protein-specific CD8<sup>+</sup> T cells compared to S-specific CD8<sup>+</sup> T cells (<xref rid="B195" ref-type="bibr">195</xref>). This highlights the importance of non-spike T cell responses contributing to protection in mild diseases. The M- and N-proteins are conserved proteins among coronaviruses and can be a potential target for a pan-coronavirus vaccine. From convalescent COVID-19 patients, CD4<sup>+</sup> T cell responses strongly correlated to anti-SARS-CoV-2 IgG and IgA titres (<xref rid="B197" ref-type="bibr">197</xref>). The same study reported 27%, 21% and 11% of the total SARS-CoV-2-specific CD4<sup>+</sup> T cells were specific for S-, M- and N-protein, respectively; with a small percentage accounting for Nsp3, Nsp4, orf3a, and orf8. The percentage of SARS-CoV-2-specific CD8<sup>+</sup> T cells included 26% for S-protein and 12% for N-protein. Immunity from natural infection reflects that vaccine approaches for SARS-CoV-2 should expand towards targeting other structural proteins, in addition to the spike protein.</p></sec><sec id="s8"><title>Cross-reactive responses towards SARS-CoV-2</title><p>Immunizations against the wild-type SARS-CoV-2 have elicited cross-reactivity towards heterologous variants of SARS-CoV-2. This includes antibody and T cell responses that cross-react with the Alpha, Beta, Gamma, Delta, and Omicron variants (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref>). Tarke et&#160;al. found that CD4<sup>+</sup>/CD8<sup>+</sup> T cells from convalescent COVID-19 patients and vaccine recipients had similar cross-reactivity towards the Alpha, Beta, Gamma, and Epsilon variants&#8212;with a reduction in cross-reactivity among the variants of 10-22% (<xref rid="B198" ref-type="bibr">198</xref>). Also, amino acid sequencing analysis revealed that only 3% and 7% of the CD4<sup>+</sup> and CD8<sup>+</sup> T cell epitopes were affected by mutations in the VOCs, respectively. The study showed that cellular immunity can induce a cross-reactive response that is highly resistant to mutations acquired by viral variants, effectively preventing VOCs from easily escaping cellular immune system defences. Theoretically, antibody and B cell epitopes are targeted towards extracellular or surface proteins of the virus, whereas T cell epitopes have comprehensive coverage of external and internal components of the virus (<xref rid="B198" ref-type="bibr">198</xref>). In addition to a broadly distributed T cell epitope repertoire, HLA-restricted T cell epitopes are different from person to person, which makes viral escape difficult to achieve.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>A pan-coronavirus vaccine that induces heterologous immunity across a wide landscape of coronaviruses needs to establish multiple immune parameters, including cross-reactive memory T responses, cross-reactive B cell and antibody responses, targeting of non-spike coronaviral proteins, and mucosal immunity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-13-952229-g003.jpg"/></fig><p>In an unexposed cohort, 40-60% of individuals had SARS-CoV-2-reactive CD4<sup>+</sup> T cells, presumably induced by previous exposure to common cold coronaviruses (<xref rid="B197" ref-type="bibr">197</xref>). These CD4<sup>+</sup> T cells have similar characteristics as the CD4<sup>+</sup> T cells obtained from vaccine and natural infection induced immunity, producing IFN-&#947;, TNF-&#945; and IL-2 (<xref rid="B199" ref-type="bibr">199</xref>). However, this population is present in higher proportions in convalescent COVID-19 patients compared to the unexposed cohort. Also, these CD4<sup>+</sup>/CD8<sup>+</sup> T cells, found in unexposed and recovered patients, are targeting non-spike viral epitopes, including N and M epitopes which are more conserved compared to spike. This suggests that T cells targeting internal components of SARS-CoV-2 virion, which are also highly conserved proteins, can potentially lead to a cross-reactive response.</p><p>SARS-CoV-2 and human endemic coronaviruses (hCoV), such as hCoV-OC43, -HKU1, -229E, and -NL63, come from different genera within the <italic toggle="yes">Coronaviridae</italic> family. Immune responses against pre-existing hCoVs have shown to cross-react with SARS-CoV-2 which has provided insight into conserved viral proteins that can potentially be targeted for a pan-coronavirus vaccine. Finnish children and adults were compared for their antibody titres to human endemic coronaviruses to see if they cross-reacted with SARS-CoV-2 (<xref rid="B200" ref-type="bibr">200</xref>). The results showed pre-existing hCoV-OC43 and hCoV-229E-specific antibodies indeed cross-reacted with SARS-CoV-2 proteins. Serum samples from children had significantly higher levels of cross-reactivity to the SARS-CoV-2 S, RBD, and N proteins (p = 0.001-0.007). Not surprisingly, the highest cross-reactivity reported was to the N-protein, already known to be highly conserved among coronaviruses. A retrospective study in macaques investigated the SARS-CoV-2 specific antibody responses against SARS-CoV-1 and MERS-CoV (<xref rid="B201" ref-type="bibr">201</xref>). The macaques were immunized with COVID-19 vaccines, followed by natural infection with SARS-CoV-2, and serum samples were collected for analysis. They reported 123-fold and 11-fold increases in antibody binding to SARS-CoV-1 and MERS-CoV S proteins, respectively, compared to sera from pre-pandemic healthy individuals. Furthermore, S-specific antibodies from convalescent COVID-19 sera displayed an increase in binding towards hCoV-OC43, hCoV-HKU1, hCoV-229E, and hCoV-NL63 by 4.2-fold, 4.3-fold, 3.8-fold, and 1.8-fold, respectively. The paper shows the implementation of current vaccines and natural infections of SARS-CoV-2 can re-boost the cross-reactive antibody responses to effectively target SARS-CoV-1, MERS-CoV, and hCoV. The author explains that broad coverage with vaccination is feasible. Considering the decline in neutralization capacity of the vaccine induced antibody response, by 1<sup>st</sup> generation COVID-19 vaccines, against the B.1.1.529 (Omicron) variants; it was unexpected that S-specific antibodies were cross-reacting to the mentioned <italic toggle="yes">Alpha-</italic> and <italic toggle="yes">Beta-coronaviruses</italic>. Further scrutiny of these cross-reactive antibodies revealed that these S-specific antibodies targeted the S<sub>2</sub> subunit of spike. Other studies have reported cross-reactive antibody sera from unexposed individual to target the S<sub>2</sub> subunit of SARS-CoV-2 and in some patients the S<sub>2</sub> antibodies had neutralization abilities (<xref rid="B202" ref-type="bibr">202</xref>, <xref rid="B203" ref-type="bibr">203</xref>). Natural infections of SARS-CoV-2 have been shown to induce both S<sub>1</sub>- and S<sub>2</sub>-specific antibodies, but only the S<sub>2</sub>-specific antibodies are able to cross-react with common cold hCoVs (<xref rid="B203" ref-type="bibr">203</xref>). Across coronaviruses, the S<sub>2</sub> subunit is more conserved compared to S<sub>1</sub>, therefore the S<sub>2</sub> subunit is more likely to cross-react. Taken together, identifying regions that induce cross-reactive antibody responses facilitates the effort towards developing a pan-coronavirus vaccine.</p><p>Looking at cellular cross-reactive responses, Grifoni et&#160;al. found that S-specific CD4<sup>+</sup>/CD8<sup>+</sup> T cells are present in 60% of unexposed individuals, with SARS-CoV-2-specific CD4<sup>+</sup> T cells making up most of the pre-existing cross-reactive T cells (<xref rid="B197" ref-type="bibr">197</xref>). Furthermore, in the unexposed cohort, memory CD4<sup>+</sup> T cells had affinity for the SARS-CoV-2 N protein, and the N protein of other coronaviruses including hCoV-OC43, hCoV-229E, hCoV-NL63, or hCoV-HKU1 (<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B204" ref-type="bibr">204</xref>). Le Bert et&#160;al. identified that memory T cells specific for N-protein from recovery patients from SARS-CoV-1, displayed a robust response against SARS-CoV-2 N protein, highlighting the cross-reactivity and long-lasting functionality of the memory subset, after 17 years (<xref rid="B205" ref-type="bibr">205</xref>). Moreover, unexposed individuals had SARS-CoV-2-specific T cell responses against the Nsp7 protein, which is also highly conserved among animal <italic toggle="yes">Betacoronaviruses</italic> (<xref rid="B205" ref-type="bibr">205</xref>). Despite the fact that the unexposed cohort demonstrated several cross-reactive memory responses, presumably derived from routine exposures from endemic human coronaviruses, a direct connection of pre-existing memory cells and improved outcomes has not been fully established.</p><p>In large part, the cellular cross-reactive responses appear to be restricted to CD4<sup>+</sup> T cell subsets, and very rarely are CD8<sup>+</sup> T cells subsets reported to cross-react against heterologous coronaviruses. The CD4<sup>+</sup> arm of the immune system plays an orchestrating role, rather than effector or killer role, therefore they cannot directly prevent infections. Instead, they are better fit to mitigate disease severity, viral burden, and reduce prolonged disease (<xref rid="B206" ref-type="bibr">206</xref>). Perhaps, the lack of cross-reactive CD8<sup>+</sup> T cells may be limiting cross-reactive responses from neutralizing the virus and eliciting protection against infections. Cao et&#160;al. and other studies suggest that CD8<sup>+</sup> memory T cell responses should become the focus of vaccine development, to provide optimal protection against SARS-CoV-2 and other coronaviruses infections (<xref rid="B207" ref-type="bibr">207</xref>, <xref rid="B208" ref-type="bibr">208</xref>).</p><p>Based on the idea that targeting conserved regions induces cross-reactive mechanisms, the SARS-CoV-2 M- and E- proteins may be potential targets to consider. Convalescent plasma from recovered SARS-CoV-2 patients show CD4<sup>+</sup>/CD8<sup>+</sup> T cell epitopes are more prevalent against M- and N-protein of SARS-CoV-2 compared to the S-protein (<xref rid="B209" ref-type="bibr">209</xref>). This study suggests vaccine development should shift focus towards targeting more stable and conserved aspects of the SARS-CoV-2 virion, such as the M-/N-protein, rather than the rapidly mutating S-protein. Recently, a study classified immunodominant T cell epitopes from patients that recovered from an acute infection of COVID-19. They found 135 epitopes, 15-mer peptides covering the envelope, membrane, and nucleocapsid proteins (<xref rid="B210" ref-type="bibr">210</xref>). There were 10 N-, M- and E- peptides that showed high affinity binding to human leukocyte antigen (HLA) class II, using <italic toggle="yes">in vitro</italic> HLA binding assays. Of these, three peptides triggered CD4<sup>+</sup>T cell responses in more than 55% of patients. Two of the three immunodominant peptides are from the M-protein, named Mem_P30 (aa146-160) and Mem_P36 (aa176-190), and one peptide is from the N-protein, Ncl_P18 (aa86-100). The identified peptides had high affinity binding to HLA-DRB1<sup>*</sup>11:01 and induced a T cell derived IFN-&#947; response (<xref rid="B210" ref-type="bibr">210</xref>). In addition, Mem_P30 and Mem_P36 were capable of binding to more than 12 HLA-molecules with an affinity of 1000nM or better. The characterization of the T cell responses and their targeted epitopes in recovered COVID-19 patients, shows a potential multi-targeted approach of vaccines directed against M, N and E structural proteins. Additionally, the paper discusses the importance of classifying epitope repertoires, as it provides a map of viral peptides that our immune system is responding to, which can be implemented in vaccine design.</p><p>To understand the landscape of SARS-CoV-2 immunodominant epitopes, we also need to consider epitopes derived from non-canonical ORFs. Due to the promiscuous nature of the SARS-CoV-2 RNA replication machinery, the virus produces alternative or out-of-frame ORFs, which can contribute to the epitope repertoire that vaccines can target. Weingarten-Gabbay et&#160;al. identified nine viral peptides originating from out-of-frame ORFs, from S and N coding regions, that were expressed on several HLA-I molecules (<xref rid="B211" ref-type="bibr">211</xref>). Also, six of the viral peptides derived from out-of-frame ORFs were predicted to bind HLA-A<sup>*</sup>02:01, which is a well-distributed HLA molecule across the human population and important in antigen presentation to T cells (<xref rid="B212" ref-type="bibr">212</xref>). Interestingly, these viral peptides were immunogenic in transgenic HLA-A2 mice, inducing a strong CD8<sup>+</sup> T cell and IFN-&#947; response. From the study, it was found that 25% of the HLA-I peptides detected were derived from out-of-frame ORFs from S and N coding regions, highlighting the ability of the immune system to target viral epitopes derived from non-canonical ORFs as well as canonical ORFs. Weingarten-Gabbay et&#160;al. has introduced the idea that viral epitopes from non-canonical ORFs can serves as vaccine targets. However, additional studies need to be conducted on the immune parameters it induces, the degree of cross-reactivity and protection against infection elicited by these viral epitopes derived from non-canonical ORFs.</p></sec><sec id="s9"><title>Conclusion</title><p>Finding the immune markers and mechanisms that confer or contribute to protection is essential in developing a pan-coronavirus vaccine. The current COVID-19 vaccines are inducing heterologous immunity, and the immunity is cross-reactive and cross-protective to a certain extent against SARS-CoV-2 VOCs. By analyzing the vaccine induced immunity from 1<sup>st</sup> generation vaccines, it is evident that antibody responses are effective at protecting against the wild-type SARS-CoV-2 and its variants. However, as SARS-CoV-2 variants accumulated mutations in the spike protein, sera from vaccine recipients declined in neutralization capabilities where protection against infection was reduced. This raised the question about the reliance of antibody responses and their ability to effectively protect the human population against SARS-CoV-2 and its variants. Secondly, it encouraged research to identify cellular immune responses that may contribute to coronavirus protection and pinpoint cross-reactive mechanisms that broaden coronavirus immunity outside of SARS-CoV-2. The correlation of protection is clearly outlined for the humoral response in terms of NAb titre levels, neutralization capacity, and the onset of the NAbs response. In contrast, cellular responses are ill-defined when it comes to protection. However, repeated examples of CD4<sup>+</sup>/CD8<sup>+</sup> T cells associated with protection against severe disease have provided some insights. Additionally, cross-reactive mechanisms identified from unexposed individuals have allowed researchers to identify conserved epitopes that induce cross-reactive immune responses and encouraged targeting viral proteins other than the spike protein. Recognition of cross-reactive immune responses have contributed to broadening the protective coverage toward other coronaviruses and made the idea of developing a universal vaccine for coronaviruses more feasible. Additionally, epitope studies and databases like IEDB assist in vaccine design and allow the targeting of selected epitopes that can produce heterologous immunity that is cross-reactive, comprehensive in coverage of SARS-CoV-2 viral proteins and other coronaviruses infections, and inducive of a long-lasting, multifaceted humoral and cellular responses.</p></sec><sec sec-type="author-contributions" id="s10"><title>Author contributions</title><p>RP and BA conceptualized the article and collected the literature. RP wrote the first draft. BA and RP revised the manuscript. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="funding-information" id="s11"><title>Funding</title><p>This work is funded by project grants (PS165854 and PS173314) from the Canadian Institutes of Health Research (CIHR) to BA.</p></sec><sec sec-type="acknowledgement" id="s12"><title>Acknowledgments</title><p>We thank Dr. M.S. Peppler for reading, editing and providing critical comments.</p></sec><sec sec-type="COI-statement" id="s13"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s14"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name></person-group>. <article-title>The emergence, genomic diversity and global spread of SARS-COV-2</article-title>. <source>Nature</source> (<year>2021</year>) <volume>600</volume>:<page-range>408&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-04188-6</pub-id><pub-id pub-id-type="pmid">34880490</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>On the origin and continuing evolution of SARS-COV-2</article-title>. <source>Natl Sci Rev</source> (<year>2020</year>) <volume>7</volume>:<page-range>1012&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id><pub-id pub-id-type="pmcid">PMC7107875</pub-id><pub-id pub-id-type="pmid">34676127</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The emergence and spread of novel SARS-COV-2 variants</article-title>. <source>Front Public Health</source> (<year>2021</year>) <volume>9</volume>:<elocation-id>696664</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fpubh.2021.696664</pub-id><pub-id pub-id-type="pmid">34409009</pub-id><pub-id pub-id-type="pmcid">PMC8364952</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <source>Novel coronavirus</source> (<year>2019</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn</uri> (Accessed <date-in-citation content-type="access-date">March 29, 2022</date-in-citation>).</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <source>Pneumonia of unknown cause &#8211; China</source> (<year>2020</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229">https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229</uri> (Accessed <date-in-citation content-type="access-date">March 29, 2022</date-in-citation>).</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <source>WHO coronavirus (COVID-19)</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.who.int/">https://covid19.who.int/</uri> (Accessed <date-in-citation content-type="access-date">March 29, 2022</date-in-citation>).</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mistry</surname><given-names>P</given-names></name><name name-style="western"><surname>Barmania</surname><given-names>F</given-names></name><name name-style="western"><surname>Mellet</surname><given-names>J</given-names></name><name name-style="western"><surname>Peta</surname><given-names>K</given-names></name><name name-style="western"><surname>Strydom</surname><given-names>A</given-names></name><name name-style="western"><surname>Viljoen</surname><given-names>IM</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 variants, vaccines, and host immunity</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>12</volume>:<elocation-id>809244</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.809244</pub-id><pub-id pub-id-type="pmid">35046961</pub-id><pub-id pub-id-type="pmcid">PMC8761766</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Yanow</surname><given-names>SK</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>B</given-names></name></person-group>. <article-title>Heterologous immunity: Implications and applications in vaccines and immunotherapies</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1408</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01408</pub-id><pub-id pub-id-type="pmid">32774334</pub-id><pub-id pub-id-type="pmcid">PMC7381340</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>B</given-names></name></person-group>. <article-title>Heterologous immunity: Role in natural and vaccine-induced resistance to infections</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2631</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02631</pub-id><pub-id pub-id-type="pmid">31781118</pub-id><pub-id pub-id-type="pmcid">PMC6856678</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Covi&#225;n</surname><given-names>C</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Fierro</surname><given-names>A</given-names></name><name name-style="western"><surname>Retamal-D&#237;az</surname><given-names>A</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>FE</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>AE</given-names></name><name name-style="western"><surname>Lay</surname><given-names>MK</given-names></name><etal/></person-group>. <article-title>BCG-Induced cross-protection and development of trained immunity: Implication for vaccine design</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2806</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02806</pub-id><pub-id pub-id-type="pmid">31849980</pub-id><pub-id pub-id-type="pmcid">PMC6896902</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youssef</surname><given-names>EG</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Alkhazraji</surname><given-names>S</given-names></name><name name-style="western"><surname>Gebremariam</surname><given-names>T</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Yount</surname><given-names>NY</given-names></name><etal/></person-group>. <article-title>Monoclonal IgM antibodies targeting <italic toggle="yes">Candida albicans</italic> Hyr1 provide cross-kingdom protection against gram-negative bacteria</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>76</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00076</pub-id><pub-id pub-id-type="pmid">32153560</pub-id><pub-id pub-id-type="pmcid">PMC7045048</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitran</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Yanow</surname><given-names>SK</given-names></name></person-group>. <article-title>The case for exploiting cross-species epitopes in malaria vaccine design</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>335</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00335</pub-id><pub-id pub-id-type="pmid">32174924</pub-id><pub-id pub-id-type="pmcid">PMC7056716</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>QT</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J</given-names></name><name name-style="western"><surname>Sung</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Poly-&#947;-glutamic acid complexed with alum induces cross-protective immunity of pandemic H1N1 vaccine</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1604</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01604</pub-id><pub-id pub-id-type="pmid">31354739</pub-id><pub-id pub-id-type="pmcid">PMC6637289</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rathore</surname><given-names>APS</given-names></name><name name-style="western"><surname>St. John</surname><given-names>AL</given-names></name></person-group>. <article-title>Cross-reactive immunity among flaviviruses</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>334</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00334</pub-id><pub-id pub-id-type="pmid">32174923</pub-id><pub-id pub-id-type="pmcid">PMC7054434</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X-L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X-G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source> (<year>2020</year>) <volume>579</volume>:<page-range>270&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2951-z</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boni</surname><given-names>MF</given-names></name><name name-style="western"><surname>Lemey</surname><given-names>P</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lam</surname><given-names>TT-Y</given-names></name><name name-style="western"><surname>Perry</surname><given-names>BW</given-names></name><name name-style="western"><surname>Castoe</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Evolutionary origins of the SARS-COV-2 sarbecovirus lineage responsible for the COVID-19 pandemic</article-title>. <source>Nat Microbiol</source> (<year>2020</year>) <volume>5</volume>:<page-range>1408&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41564-020-0771-4</pub-id><pub-id pub-id-type="pmid">32724171</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-COV-2 and related viruses</article-title>. <source>Cell</source> (<year>2021</year>) <volume>184</volume>:<page-range>4380&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.06.008</pub-id><pub-id pub-id-type="pmcid">PMC8188299</pub-id><pub-id pub-id-type="pmid">34147139</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>TT-Y</given-names></name><name name-style="western"><surname>Jia</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y-W</given-names></name><name name-style="western"><surname>Shum</surname><given-names>MH-H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J-F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H-C</given-names></name><etal/></person-group>. <article-title>Identifying sars-COV-2-related coronaviruses in Malayan pangolins</article-title>. <source>Nature</source> (<year>2020</year>) <volume>583</volume>:<page-range>282&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2169-0</pub-id><pub-id pub-id-type="pmid">32218527</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J-J</given-names></name><etal/></person-group>. <article-title>Isolation of SARS-COV-2-related coronavirus from Malayan pangolins</article-title>. <source>Nature</source> (<year>2020</year>) <volume>583</volume>:<page-range>286&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2313-x</pub-id><pub-id pub-id-type="pmid">32380510</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>AMQ</given-names></name><name name-style="western"><surname>Adams</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Carstens</surname><given-names>EB</given-names></name><name name-style="western"><surname>Lefkowitz</surname><given-names>EJ</given-names></name></person-group>. <article-title>Family &#8211; coronaviridae</article-title>. In: <source>Virus taxonomy</source>. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Elsevier</publisher-name> (<year>2012</year>). p. <page-range>806&#8211;28</page-range>.</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Pathogenicity, tissue tropism and potential vertical transmission of SARSr-CoV-2 in Malayan pangolins</article-title>. <source>bioRxiv</source> (<year>2020</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2020.06.22.164442</pub-id><pub-id pub-id-type="pmcid">PMC10228812</pub-id><pub-id pub-id-type="pmid">37196026</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousavizadeh</surname><given-names>L</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>S</given-names></name></person-group>. <article-title>Genotype and phenotype of covid-19: Their roles in pathogenesis</article-title>. <source>J Microbiol Immunol Infection</source> (<year>2021</year>) <volume>54</volume>:<page-range>159&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jmii.2020.03.022</pub-id><pub-id pub-id-type="pmcid">PMC7138183</pub-id><pub-id pub-id-type="pmid">32265180</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D</given-names></name></person-group>. <article-title>Structural insights into coronavirus entry</article-title>. <source>Adv Virus Res</source> (<year>2019</year>) <volume>105</volume>:<fpage>93</fpage>&#8211;<lpage>116</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/bs.aivir.2019.08.002</pub-id><pub-id pub-id-type="pmid">31522710</pub-id><pub-id pub-id-type="pmcid">PMC7112261</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paules</surname><given-names>CI</given-names></name><name name-style="western"><surname>Marston</surname><given-names>HD</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name></person-group>. <article-title>Coronavirus infections&#8211;more than just the common cold</article-title>. <source>JAMA</source> (<year>2020</year>) <volume>323</volume>:<page-range>707&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2020.0757</pub-id><pub-id pub-id-type="pmid">31971553</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>DE</given-names></name><name name-style="western"><surname>Jang</surname><given-names>GM</given-names></name><name name-style="western"><surname>Bouhaddou</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Obernier</surname><given-names>K</given-names></name><name name-style="western"><surname>White</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>A SARS-COV-2 protein interaction map reveals targets for drug repurposing</article-title>. <source>Nature</source> (<year>2020</year>) <volume>583</volume>:<page-range>459&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id><pub-id pub-id-type="pmcid">PMC7431030</pub-id><pub-id pub-id-type="pmid">32353859</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariano</surname><given-names>G</given-names></name><name name-style="western"><surname>Farthing</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lale-Farjat</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bergeron</surname><given-names>JR</given-names></name></person-group>. <article-title>Structural characterization of SARS-COV-2: Where we are, and where we need to be</article-title>. <source>Front Mol Biosci</source> (<year>2020</year>) <volume>7</volume>:<elocation-id>605236</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmolb.2020.605236</pub-id><pub-id pub-id-type="pmid">33392262</pub-id><pub-id pub-id-type="pmcid">PMC7773825</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>L</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bao</surname><given-names>QY</given-names></name><name name-style="western"><surname>Tian</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Feng</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Polymorphism of SARS-COV genomes</article-title>. <source>Acta Genetica Sin</source> (<year>2006</year>) <volume>33</volume>:<page-range>354&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0379-4172(06)60061-9</pub-id><pub-id pub-id-type="pmcid">PMC7131822</pub-id><pub-id pub-id-type="pmid">16625834</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammad</surname><given-names>T</given-names></name><name name-style="western"><surname>Choudhury</surname><given-names>A</given-names></name><name name-style="western"><surname>Habib</surname><given-names>I</given-names></name><name name-style="western"><surname>Asrani</surname><given-names>P</given-names></name><name name-style="western"><surname>Mathur</surname><given-names>Y</given-names></name><name name-style="western"><surname>Umair</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Genomic variations in the structural proteins of SARS-COV-2 and their deleterious impact on pathogenesis: A comparative genomics approach</article-title>. <source>Front Cell Infection Microbiol</source> (<year>2021</year>) <volume>11</volume>:<elocation-id>765039</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2021.765039</pub-id><pub-id pub-id-type="pmcid">PMC8548870</pub-id><pub-id pub-id-type="pmid">34722346</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosch</surname><given-names>BJ</given-names></name><name name-style="western"><surname>van der Zee</surname><given-names>R</given-names></name><name name-style="western"><surname>de Haan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>PJ</given-names></name></person-group>. <article-title>The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex</article-title>. <source>J Virol</source> (<year>2003</year>) <volume>77</volume>:<page-range>8801&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/jvi.77.16.8801-8811.2003</pub-id><pub-id pub-id-type="pmcid">PMC167208</pub-id><pub-id pub-id-type="pmid">12885899</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>N</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell</source> (<year>2020</year>) <volume>181</volume>:<page-range>271&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A novel bat coronavirus closely related to SARS-COV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein</article-title>. <source>Curr Biol</source> (<year>2020</year>) <volume>30</volume>:<page-range>2196&#8211;203</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cub.2020.05.023</pub-id><pub-id pub-id-type="pmcid">PMC7211627</pub-id><pub-id pub-id-type="pmid">32416074</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>TN</given-names></name><name name-style="western"><surname>Greaney</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hilton</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>D</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>KHD</given-names></name><name name-style="western"><surname>Dingens</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Deep mutational scanning of SARS-COV-2 receptor binding domain reveals constraints on folding and Ace2 binding</article-title>. <source>Cell</source> (<year>2020</year>) <volume>182</volume>:<page-range>1295&#8211;310</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.08.012</pub-id><pub-id pub-id-type="pmcid">PMC7418704</pub-id><pub-id pub-id-type="pmid">32841599</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makowski</surname><given-names>L</given-names></name><name name-style="western"><surname>Olson-Sidford</surname><given-names>W</given-names></name><name name-style="western"><surname>Weisel</surname><given-names>J</given-names></name></person-group>. <article-title>Biological and clinical consequences of integrin binding <italic toggle="yes">via</italic> a rogue RGD motif in the SARS COV-2 spike protein</article-title>. <source>Viruses</source> (<year>2021</year>) <volume>13</volume>:<elocation-id>146</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/v13020146</pub-id><pub-id pub-id-type="pmid">33498225</pub-id><pub-id pub-id-type="pmcid">PMC7909284</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>K</given-names></name><name name-style="western"><surname>Shum</surname><given-names>MHH</given-names></name><name name-style="western"><surname>Leung</surname><given-names>GM</given-names></name><name name-style="western"><surname>Lam</surname><given-names>TTY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JT</given-names></name></person-group>. <article-title>Early transmissibility assessment of the N501Y mutant strains of SARS-COV-2 in the united kingdom, October to November 2020</article-title>. <source>Eurosurveillance</source> (<year>2021</year>) <volume>26</volume>:<elocation-id>2002106</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.2807/1560-7917.es.2020.26.1.2002106</pub-id><pub-id pub-id-type="pmcid">PMC7791602</pub-id><pub-id pub-id-type="pmid">33413740</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JD</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Crispin</surname><given-names>M</given-names></name></person-group>. <article-title>Site-specific glycan analysis of the SARS-COV-2 spike</article-title>. <source>Science</source> (<year>2020</year>) <volume>369</volume>:<page-range>330&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abb9983</pub-id><pub-id pub-id-type="pmcid">PMC7199903</pub-id><pub-id pub-id-type="pmid">32366695</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegally</surname><given-names>H</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>E</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Iranzadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>V</given-names></name><name name-style="western"><surname>Giandhari</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Detection of a SARS-COV-2 variant of concern in south Africa</article-title>. <source>Nature</source> (<year>2021</year>) <volume>592</volume>:<page-range>438&#8211;43</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03402-9</pub-id><pub-id pub-id-type="pmid">33690265</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>NR</given-names></name><name name-style="western"><surname>Claro</surname><given-names>I</given-names></name><name name-style="western"><surname>Candido</surname><given-names>D</given-names></name><name name-style="western"><surname>Franco</surname><given-names>LA</given-names></name><name name-style="western"><surname>Pamela</surname><given-names>AS</given-names></name><name name-style="western"><surname>Coletti</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>Genomic characterisation of an emergent SARSCoV-2 lineage in manaus: Preliminary findings</article-title> (<year>2021</year>). virological.org. Available at:<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://virological.org/t/genomic-characterisation-of-anemergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586">https://virological.org/t/genomic-characterisation-of-anemergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586</uri> (Accessed April 1, 2022).</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fratev</surname><given-names>F</given-names></name></person-group>. <article-title>N501Y and K417N mutations in the spike protein of SARS-COV-2 alter the interactions with both hACE2 and human-derived antibody: A free energy of perturbation retrospective study</article-title>. <source>J Chem Inf Modeling</source> (<year>2021</year>) <volume>61</volume>:<page-range>6079&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.jcim.1c01242</pub-id><pub-id pub-id-type="pmid">34806876</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huh</surname><given-names>K</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MY</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J-H</given-names></name><etal/></person-group>. <article-title>Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (covid-19) outbreak in Korea: A nationwide surveillance study</article-title>. <source>Clin Infect Dis</source> (<year>2020</year>) <volume>72</volume>:<page-range>184&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/cid/ciaa1682</pub-id><pub-id pub-id-type="pmcid">PMC7665442</pub-id><pub-id pub-id-type="pmid">33150393</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jangra</surname><given-names>S</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C</given-names></name><name name-style="western"><surname>Rathnasinghe</surname><given-names>R</given-names></name><name name-style="western"><surname>Stadlbauer</surname><given-names>D</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>F</given-names></name><name name-style="western"><surname>Simon</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 spike E484K mutation reduces antibody neutralisation</article-title>. <source>Lancet Microbe</source> (<year>2021</year>) <volume>2</volume>:<page-range>283&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s2666-5247(21)00068-9</pub-id><pub-id pub-id-type="pmcid">PMC8026167</pub-id><pub-id pub-id-type="pmid">33846703</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreano</surname><given-names>E</given-names></name><name name-style="western"><surname>Piccini</surname><given-names>G</given-names></name><name name-style="western"><surname>Licastro</surname><given-names>D</given-names></name><name name-style="western"><surname>Casalino</surname><given-names>L</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>NV</given-names></name><name name-style="western"><surname>Paciello</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma</article-title>. <source>Proceedings of the National Academy of Sciences</source> (<year>2021</year>) <volume>118</volume>:<elocation-id>e2103154118</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.2103154118</pub-id><pub-id pub-id-type="pmcid">PMC8433494</pub-id><pub-id pub-id-type="pmid">34417349</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Socher</surname><given-names>E</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>M</given-names></name><name name-style="western"><surname>Heger</surname><given-names>L</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>F</given-names></name><name name-style="western"><surname>Sticht</surname><given-names>H</given-names></name><name name-style="western"><surname>Zunke</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Mutations in the B.1.1.7 SARS-COV-2 spike protein reduce receptor-binding affinity and induce a flexible link to the fusion peptide</article-title>. <source>Biomedicines</source> (<year>2021</year>) <volume>9</volume>:<elocation-id>525</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biomedicines9050525</pub-id><pub-id pub-id-type="pmid">34066729</pub-id><pub-id pub-id-type="pmcid">PMC8151884</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plante</surname><given-names>JA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>BA</given-names></name><name name-style="western"><surname>Lokugamage</surname><given-names>KG</given-names></name><etal/></person-group>. <article-title>Spike mutation D614G alters SARS-COV-2 fitness</article-title>. <source>Nature</source> (<year>2020</year>) <volume>592</volume>:<page-range>116&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2895-3</pub-id><pub-id pub-id-type="pmcid">PMC8158177</pub-id><pub-id pub-id-type="pmid">33106671</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostrov</surname><given-names>DA</given-names></name></person-group>. <article-title>Structural consequences of variation in SARS-COV-2 B.1.1.7</article-title>. <source>J Cell Immunol</source> (<year>2021</year>) <volume>3</volume>:<page-range>103&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.33696/immunology.3.085</pub-id><pub-id pub-id-type="pmcid">PMC8104447</pub-id><pub-id pub-id-type="pmid">33969357</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubinski</surname><given-names>B</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>MH</given-names></name><name name-style="western"><surname>Frazier</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>S</given-names></name><name name-style="western"><surname>Diel</surname><given-names>DG</given-names></name><etal/></person-group>. <article-title>Functional evaluation of the P681H mutation on the proteolytic activation the SARS-COV-2 variant B.1.1.7 (alpha) spike</article-title>. <source>iScience</source> (<year>2022</year>) <volume>25</volume>:<elocation-id>103589</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.isci.2021.103589</pub-id><pub-id pub-id-type="pmid">34909610</pub-id><pub-id pub-id-type="pmcid">PMC8662955</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoeman</surname><given-names>D</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>BC</given-names></name></person-group>. <article-title>Coronavirus envelope protein: Current knowledge</article-title>. <source>Virol J</source> (<year>2019</year>) <volume>16</volume>:<fpage>1</fpage>&#8211;<lpage>22</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12985-019-1182-0</pub-id><pub-id pub-id-type="pmid">31133031</pub-id><pub-id pub-id-type="pmcid">PMC6537279</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name name-style="western"><surname>DeDiego</surname><given-names>ML</given-names></name><name name-style="western"><surname>&#193;lvarez</surname><given-names>E</given-names></name><name name-style="western"><surname>Jim&#233;nez-Guarde&#241;o</surname><given-names>JM</given-names></name><name name-style="western"><surname>Regla-Nava</surname><given-names>JA</given-names></name><name name-style="western"><surname>Llorente</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein</article-title>. <source>Virology</source> (<year>2011</year>) <volume>415</volume>:<fpage>69</fpage>&#8211;<lpage>82</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.virol.2011.03.029</pub-id><pub-id pub-id-type="pmid">21524776</pub-id><pub-id pub-id-type="pmcid">PMC4726981</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdi&#225;-B&#225;guena</surname><given-names>C</given-names></name><name name-style="western"><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name name-style="western"><surname>Alcaraz</surname><given-names>A</given-names></name><name name-style="western"><surname>DeDiego</surname><given-names>ML</given-names></name><name name-style="western"><surname>Torres</surname><given-names>J</given-names></name><name name-style="western"><surname>Aguilella</surname><given-names>VM</given-names></name><etal/></person-group>. <article-title>Coronavirus e protein forms ion channels with functionally and structurally-involved membrane lipids</article-title>. <source>Virology</source> (<year>2012</year>) <volume>432</volume>:<page-range>485&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.virol.2012.07.005</pub-id><pub-id pub-id-type="pmcid">PMC3438407</pub-id><pub-id pub-id-type="pmid">22832120</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name name-style="western"><surname>DeDiego</surname><given-names>ML</given-names></name><name name-style="western"><surname>Verdi&#225;-B&#225;guena</surname><given-names>C</given-names></name><name name-style="western"><surname>Jimenez-Guarde&#241;o</surname><given-names>JM</given-names></name><name name-style="western"><surname>Regla-Nava</surname><given-names>JA</given-names></name><name name-style="western"><surname>Fernandez-Delgado</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis</article-title>. <source>PLoS Pathogens</source> (<year>2014</year>) <volume>10</volume>:<elocation-id>e1004077</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1004077</pub-id><pub-id pub-id-type="pmid">24788150</pub-id><pub-id pub-id-type="pmcid">PMC4006877</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chellasamy</surname><given-names>G</given-names></name><name name-style="western"><surname>Arumugasamy</surname><given-names>SK</given-names></name><name name-style="western"><surname>Govindaraju</surname><given-names>S</given-names></name><name name-style="western"><surname>Yun</surname><given-names>K</given-names></name></person-group>. <article-title>Analytical insights of COVID-19 pandemic</article-title>. <source>TrAC Trends Analytical Chem</source> (<year>2020</year>) <volume>133</volume>:<elocation-id>116072</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.trac.2020.116072</pub-id><pub-id pub-id-type="pmcid">PMC7567672</pub-id><pub-id pub-id-type="pmid">33100439</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizwan</surname><given-names>T</given-names></name><name name-style="western"><surname>Kothidar</surname><given-names>A</given-names></name><name name-style="western"><surname>Meghwani</surname><given-names>H</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>V</given-names></name><name name-style="western"><surname>Shobhawat</surname><given-names>R</given-names></name><name name-style="western"><surname>Saini</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Comparative analysis of SARS-COV-2 envelope viroporin mutations from COVID-19 deceased and surviving patients revealed implications on its ion-channel activities and correlation with patient mortality</article-title>. <source>J Biomol Struct Dyn</source> (<year>2021</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>16</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/07391102.2021.1944319</pub-id><pub-id pub-id-type="pmid">34229570</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahtarin</surname><given-names>R</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>MO</given-names></name><name name-style="western"><surname>Ali</surname><given-names>MA</given-names></name><name name-style="western"><surname>Halim</surname><given-names>MA</given-names></name></person-group>. <article-title>Structure and dynamics of membrane protein in SARS-COV-2</article-title>. <source>J Biomol Struct Dyn</source> (<year>2020</year>) <volume>40</volume>:<page-range>4725&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/07391102.2020.1861983</pub-id><pub-id pub-id-type="pmcid">PMC7784837</pub-id><pub-id pub-id-type="pmid">33353499</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuman</surname><given-names>BW</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>G</given-names></name><name name-style="western"><surname>Kunding</surname><given-names>AH</given-names></name><name name-style="western"><surname>Bhella</surname><given-names>D</given-names></name><name name-style="western"><surname>Baksh</surname><given-names>MF</given-names></name><name name-style="western"><surname>Connelly</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A structural analysis of m protein in coronavirus assembly and morphology</article-title>. <source>J Struct Biol</source> (<year>2011</year>) <volume>174</volume>:<fpage>11</fpage>&#8211;<lpage>22</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jsb.2010.11.021</pub-id><pub-id pub-id-type="pmid">21130884</pub-id><pub-id pub-id-type="pmcid">PMC4486061</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Benvenuto</surname><given-names>D</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Angeletti</surname><given-names>S</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Pascarella</surname><given-names>S</given-names></name></person-group>. <article-title>SARS-COV-2 envelope and membrane proteins: Structural differences linked to virus characteristics</article-title>? <source>BioMed Res Int</source> (<year>2020</year>) <volume>2020</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2020/4389089</pub-id><pub-id pub-id-type="pmcid">PMC7261327</pub-id><pub-id pub-id-type="pmid">32596311</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troyano-Hern&#225;ez</surname><given-names>P</given-names></name><name name-style="western"><surname>Reinosa</surname><given-names>R</given-names></name><name name-style="western"><surname>Holgu&#237;n</surname><given-names>&#193;</given-names></name></person-group>. <article-title>Evolution of SARS-COV-2 envelope, membrane, nucleocapsid, and spike structural proteins from the beginning of the pandemic to September 2020: A global and regional approach by epidemiological week</article-title>. <source>Viruses</source> (<year>2021</year>) <volume>13</volume>:<elocation-id>243</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/v13020243</pub-id><pub-id pub-id-type="pmid">33557213</pub-id><pub-id pub-id-type="pmcid">PMC7913946</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakhmola</surname><given-names>S</given-names></name><name name-style="western"><surname>Indari</surname><given-names>O</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>D</given-names></name><name name-style="western"><surname>Varshney</surname><given-names>N</given-names></name><name name-style="western"><surname>Das</surname><given-names>A</given-names></name><name name-style="western"><surname>Manivannan</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Mutational analysis of structural proteins of SARS-COV-2</article-title>. <source>Heliyon</source> (<year>2021</year>) <volume>7</volume>:<elocation-id>e06572</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e06572</pub-id><pub-id pub-id-type="pmid">33778179</pub-id><pub-id pub-id-type="pmcid">PMC7980187</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McBride</surname><given-names>R</given-names></name><name name-style="western"><surname>van Zyl</surname><given-names>M</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>B</given-names></name></person-group>. <article-title>The coronavirus nucleocapsid is a multifunctional protein</article-title>. <source>Viruses</source> (<year>2014</year>) <volume>6</volume>:<fpage>2991</fpage>&#8211;<lpage>3018</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/v6082991</pub-id><pub-id pub-id-type="pmid">25105276</pub-id><pub-id pub-id-type="pmcid">PMC4147684</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C-K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C-MM</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>M-H</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T-H</given-names></name></person-group>. <article-title>Transient oligomerization of the SARS-COV n protein &#8211; implication for virus ribonucleoprotein packaging</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e65045</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0065045</pub-id><pub-id pub-id-type="pmid">23717688</pub-id><pub-id pub-id-type="pmcid">PMC3662775</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C-K</given-names></name><name name-style="western"><surname>Hou</surname><given-names>M-H</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C-F</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>C-D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T-H</given-names></name></person-group>. <article-title>The SARS coronavirus nucleocapsid protein &#8211; forms and functions</article-title>. <source>Antiviral Res</source> (<year>2014</year>) <volume>103</volume>:<fpage>39</fpage>&#8211;<lpage>50</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.antiviral.2013.12.009</pub-id><pub-id pub-id-type="pmid">24418573</pub-id><pub-id pub-id-type="pmcid">PMC7113676</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C-K</given-names></name><name name-style="western"><surname>Sue</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T-h</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C-M</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C-K</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>Y-C</given-names></name><etal/></person-group>. <article-title>Modular organization of SARS coronavirus nucleocapsid protein</article-title>. <source>J Biomed Sci</source> (<year>2005</year>) <volume>13</volume>:<fpage>59</fpage>&#8211;<lpage>72</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11373-005-9035-9</pub-id><pub-id pub-id-type="pmid">16228284</pub-id><pub-id pub-id-type="pmcid">PMC7089556</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naqvi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>K</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>T</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>U</given-names></name><name name-style="western"><surname>Singh</surname><given-names>IK</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Insights into SARS-COV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach</article-title>. <source>Biochim Biophys Acta (BBA) - Mol Basis Dis</source> (<year>2020</year>) <volume>1866</volume>:<elocation-id>165878</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165878</pub-id><pub-id pub-id-type="pmcid">PMC7293463</pub-id><pub-id pub-id-type="pmid">32544429</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leary</surname><given-names>S</given-names></name><name name-style="western"><surname>Gaudieri</surname><given-names>S</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>A</given-names></name><name name-style="western"><surname>James</surname><given-names>I</given-names></name><name name-style="western"><surname>Pakala</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Generation of a novel SARS-COV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: Homologous recombination has potential to change SARS-COV-2 at both protein and RNA level</article-title>. <source>Pathog Immun</source> (<year>2021</year>) <volume>6</volume>:<fpage>27</fpage>&#8211;<lpage>49</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.20411/pai.v6i2.460</pub-id><pub-id pub-id-type="pmid">34541432</pub-id><pub-id pub-id-type="pmcid">PMC8439434</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomaszewski</surname><given-names>T</given-names></name><name name-style="western"><surname>DeVries</surname><given-names>RS</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>G</given-names></name><name name-style="western"><surname>Norsworthy</surname><given-names>MD</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>New pathways of mutational change in SARS-COV-2 proteomes involve regions of intrinsic disorder important for virus replication and release</article-title>. <source>Evolutionary Bioinf</source> (<year>2020</year>) <volume>16</volume>:<elocation-id>117693432096514</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1176934320965149</pub-id><pub-id pub-id-type="pmcid">PMC7586267</pub-id><pub-id pub-id-type="pmid">33149541</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Giorgio</surname><given-names>S</given-names></name><name name-style="western"><surname>Martignano</surname><given-names>F</given-names></name><name name-style="western"><surname>Torcia</surname><given-names>MG</given-names></name><name name-style="western"><surname>Mattiuz</surname><given-names>G</given-names></name><name name-style="western"><surname>Conticello</surname><given-names>SG</given-names></name></person-group>. <article-title>Evidence for host-dependent RNA editing in the transcriptome of SARS-COV-2</article-title>. <source>Sci Adv</source> (<year>2020</year>) <volume>6</volume>:<elocation-id>eabb5813</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciadv.abb5813</pub-id><pub-id pub-id-type="pmid">32596474</pub-id><pub-id pub-id-type="pmcid">PMC7299625</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>CM</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>B</given-names></name><name name-style="western"><surname>Burger</surname><given-names>H</given-names></name><name name-style="western"><surname>Doerfler</surname><given-names>W</given-names></name></person-group>. <article-title>SARS-COV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: A time-course study &#8211; potential challenge for vaccines and therapies</article-title>. <source>EMBO Mol Med</source> (<year>2021</year>) <volume>13</volume>:<elocation-id>e14062</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.15252/emmm.202114062</pub-id><pub-id pub-id-type="pmid">33931941</pub-id><pub-id pub-id-type="pmcid">PMC8185546</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mourier</surname><given-names>T</given-names></name><name name-style="western"><surname>Sadykov</surname><given-names>M</given-names></name><name name-style="western"><surname>Carr</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>G</given-names></name><name name-style="western"><surname>Hall</surname><given-names>WW</given-names></name><name name-style="western"><surname>Pain</surname><given-names>A</given-names></name></person-group>. <article-title>Host-directed editing of the SARS-COV-2 genome</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2021</year>) <volume>538</volume>:<page-range>35&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.092</pub-id><pub-id pub-id-type="pmcid">PMC7643664</pub-id><pub-id pub-id-type="pmid">33234239</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathak</surname><given-names>AK</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>GP</given-names></name><name name-style="western"><surname>Uppili</surname><given-names>B</given-names></name><name name-style="western"><surname>Walia</surname><given-names>S</given-names></name><name name-style="western"><surname>Fatihi</surname><given-names>S</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Spatio-temporal dynamics of intra-host variability in SARS-COV-2 genomes</article-title>. <source>Nucleic Acids Res</source> (<year>2022</year>) <volume>50</volume>:<page-range>1551&#8211;61</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkab1297</pub-id><pub-id pub-id-type="pmcid">PMC8860616</pub-id><pub-id pub-id-type="pmid">35048970</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Giorgi</surname><given-names>EE</given-names></name><name name-style="western"><surname>Marichannegowda</surname><given-names>MH</given-names></name><name name-style="western"><surname>Foley</surname><given-names>B</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X-P</given-names></name><etal/></person-group>. <article-title>Emergence of SARS-COV-2 through recombination and strong purifying selection</article-title>. <source>Sci Adv</source> (<year>2020</year>) <volume>6</volume>:<elocation-id>9153</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciadv.abb9153</pub-id><pub-id pub-id-type="pmcid">PMC7458444</pub-id><pub-id pub-id-type="pmid">32937441</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ignatieva</surname><given-names>A</given-names></name><name name-style="western"><surname>Hein</surname><given-names>J</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>PA</given-names></name></person-group>. <article-title>Ongoing recombination in SARS-COV-2 revealed through genealogical reconstruction</article-title>. <source>Molecular Biology and Evolution</source> (<year>2022</year>) <volume>39</volume>:<elocation-id>msac028</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1093/molbev/msac028</pub-id><pub-id pub-id-type="pmid">35106601</pub-id><pub-id pub-id-type="pmcid">PMC8841603</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francisco</surname><given-names>JrR</given-names></name><name name-style="western"><surname>Benites</surname><given-names>LF</given-names></name><name name-style="western"><surname>Lamarca</surname><given-names>AP</given-names></name><name name-style="western"><surname>de Almeida</surname><given-names>LGP</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>AW</given-names></name><name name-style="western"><surname>Gularte</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>Pervasive transmission of E484k and emergence of vui-NP13L with evidence of SARS-COV-2 co-infection events by two different lineages in Rio grande do sul, Brazil</article-title>. <source>Virus Res</source> (<year>2021</year>) <volume>296</volume>:<elocation-id>198345</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.virusres.2021.198345</pub-id><pub-id pub-id-type="pmid">33631222</pub-id><pub-id pub-id-type="pmcid">PMC7898980</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>B</given-names></name><name name-style="western"><surname>Boni</surname><given-names>MF</given-names></name><name name-style="western"><surname>Bull</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Colleran</surname><given-names>A</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>RM</given-names></name><name name-style="western"><surname>Darby</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Generation and transmission of interlineage recombinants in the SARS-COV-2 pandemic</article-title>. <source>Cell</source> (<year>2021</year>) <volume>184</volume>:<page-range>5179&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.08.014</pub-id><pub-id pub-id-type="pmcid">PMC8367733</pub-id><pub-id pub-id-type="pmid">34499854</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <source>SARS-COV-2 variant classifications and definitions</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html">https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html</uri>.</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>McDanal</surname><given-names>C</given-names></name><name name-style="western"><surname>Wagh</surname><given-names>K</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>W</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines</article-title>. <source>Cell Host Microbe</source> (<year>2021</year>) <volume>29</volume>:<page-range>529&#8211;39</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.chom.2021.03.002</pub-id><pub-id pub-id-type="pmcid">PMC7934674</pub-id><pub-id pub-id-type="pmid">33705729</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>F</given-names></name><name name-style="western"><surname>Tong</surname><given-names>B</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>N501Y mutation of spike protein in SARS-COV-2 strengthens its binding to receptor ACE2</article-title>. <source>eLife</source> (<year>2021</year>) <volume>10</volume>:<elocation-id>e69091</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.7554/elife.69091</pub-id><pub-id pub-id-type="pmid">34414884</pub-id><pub-id pub-id-type="pmcid">PMC8455130</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Collaborating Centre for Infectious Disease</collab></person-group>. <source>Updates on COVID-19 variants of concern (VOC)</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nccid.ca/covid-19-variants/">https://nccid.ca/covid-19-variants/</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>CoVariants</collab></person-group>. <source>Overview of Variants/Mutations</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covariants.org/variants">https://covariants.org/variants</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Cov-lineages.org</collab></person-group>. <source>Global lineage reports</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cov-lineages.org/index.html">https://cov-lineages.org/index.html</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kemp</surname><given-names>SA</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Ferriera</surname><given-names>IATM</given-names></name><name name-style="western"><surname>Datir</surname><given-names>R</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>WT</given-names></name><name name-style="western"><surname>Collier</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Recurrent emergence and transmission of a SARS-COV-2 spike deletion H69/V70 and its role in the alpha variant B.1.1.7</article-title>. <source>Cell Reports</source> (<year>2021</year>) <volume>35</volume>:<elocation-id>109292</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2021.109292</pub-id><pub-id pub-id-type="pmid">34166617</pub-id><pub-id pub-id-type="pmcid">PMC8185188</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Government of UK-Public Health England</collab></person-group>. <source>Confirmed cases of COVID-19 variants identified in UK</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gov.uk/government/news/confirmed-cases-of-covid-19-variants-identified-in-uk">https://www.gov.uk/government/news/confirmed-cases-of-covid-19-variants-identified-in-uk</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Canadian Broadcasting Corporation</collab></person-group>. <source>Ontario identifies 1st cases of COVID-19 variant detected in the U.K</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cbc.ca/news/canada/toronto/ontario-confirms-first-cases-covid19-uk-variant-1.5855361">https://www.cbc.ca/news/canada/toronto/ontario-confirms-first-cases-covid19-uk-variant-1.5855361</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Science Table COVID-19 Advisory For Ontario</collab></person-group>. <source>Update on COVID-19 projections</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19-sciencetable.ca/sciencebrief/update-on-covid-19-projections-16/">https://covid19-sciencetable.ca/sciencebrief/update-on-covid-19-projections-16/</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Global News</collab></person-group>. <source>Variants could drive spike in severe outcomes for young people</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://globalnews.ca/news/7713917/covid-canada-young-people-cases-variants">https://globalnews.ca/news/7713917/covid-canada-young-people-cases-variants</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Cov-lineages.org</collab></person-group>. <source>B.1.351 2022-04-05</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cov-lineages.org/global_report_B.1.351.html">https://cov-lineages.org/global_report_B.1.351.html</uri> (Accessed <date-in-citation content-type="access-date">April 5, 2022</date-in-citation>).</mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <source>Science brief: Emerging SARS-CoV-2 variants</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).<pub-id pub-id-type="pmid">34009774</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Dejnirattisai</surname><given-names>W</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Evidence of escape of SARS-COV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>. <source>Cell</source> (<year>2021</year>) <volume>184</volume>:<page-range>2348&#8211;61</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.02.037</pub-id><pub-id pub-id-type="pmcid">PMC7901269</pub-id><pub-id pub-id-type="pmid">33730597</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>GN</given-names></name><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></name><name name-style="western"><surname>Nyayanit</surname><given-names>DA</given-names></name><name name-style="western"><surname>Patil</surname><given-names>DY</given-names></name><etal/></person-group>. <article-title>Neutralization against B.1.351 and B.1.617.2 with sera of covid-19 recovered cases and vaccinees of BBV152</article-title>. <source>bioRxiv</source> (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.06.05.447177</pub-id><pub-id pub-id-type="pmcid">PMC8344909</pub-id><pub-id pub-id-type="pmid">34230972</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Fontes-Garfias</surname><given-names>CR</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Neutralizing activity of BNT162B2-elicited serum</article-title>. <source>New Engl J Med</source> (<year>2021</year>) <volume>384</volume>:<page-range>1466&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmc2102017</pub-id><pub-id pub-id-type="pmcid">PMC7944950</pub-id><pub-id pub-id-type="pmid">33684280</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekker</surname><given-names>L-G</given-names></name><name name-style="western"><surname>Ntusi</surname><given-names>NA</given-names></name></person-group>. <article-title>Lessons from two SARS-COV-2 waves in south Africa</article-title>. <source>Lancet Global Health</source> (<year>2021</year>) <volume>9</volume>:<page-range>1177&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s2214-109x(21)00313-2</pub-id><pub-id pub-id-type="pmcid">PMC8270540</pub-id><pub-id pub-id-type="pmid">34252380</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>South African Broadcasting Corporation News</collab></person-group>. <source>New variant of coronavirus 50% more infectious</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sabcnews.com/new-variant-of-coronavirus-50-more-infectious-professor-karim">https://sabcnews.com/new-variant-of-coronavirus-50-more-infectious-professor-karim</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).</mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Public Health Ontario</collab></person-group>. <source>. COVID-19 B.1.351 (501Y.V2) variant of concern&#8211;what we know so far</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.publichealthontario.ca/-/media/documents/ncov/covid-wwksf/2021/02/wwksf-covid-19-b1351501yv2-variant-of-concern.pdf?la=en">https://www.publichealthontario.ca/-/media/documents/ncov/covid-wwksf/2021/02/wwksf-covid-19-b1351501yv2-variant-of-concern.pdf?la=en</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>NR</given-names></name><name name-style="western"><surname>Mellan</surname><given-names>TA</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>C</given-names></name><name name-style="western"><surname>Claro</surname><given-names>IM</given-names></name><name name-style="western"><surname>Candido</surname><given-names>DDA</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genomics and epidemiology of the P.1 SARS-COV-2 lineage in manaus, Brazil</article-title>. <source>Science</source> (<year>2021</year>) <volume>372</volume>:<page-range>815&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abh2644</pub-id><pub-id pub-id-type="pmcid">PMC8139423</pub-id><pub-id pub-id-type="pmid">33853970</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Cov-lineages.org</collab></person-group>. <source>P.1 2022-04-05</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cov-lineages.org/global_report_P.1.html">https://cov-lineages.org/global_report_P.1.html</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coutinho</surname><given-names>RM</given-names></name><name name-style="western"><surname>Marquitti</surname><given-names>FM</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>LS</given-names></name><name name-style="western"><surname>Borges</surname><given-names>ME</given-names></name><name name-style="western"><surname>Paix&#227;o da Silva</surname><given-names>RL</given-names></name><name name-style="western"><surname>Canton</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Model-based estimation of transmissibility and reinfection of SARS-COV-2 p. 1 variant</article-title>. <source>Communications Medicine</source> (<year>2021</year>) <volume>1</volume>:<page-range>48&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s43856-021-00048-6</pub-id><pub-id pub-id-type="pmcid">PMC9053218</pub-id><pub-id pub-id-type="pmid">35602219</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>NR</given-names></name><name name-style="western"><surname>Mellan</surname><given-names>TA</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>C</given-names></name><name name-style="western"><surname>Claro</surname><given-names>IM</given-names></name><name name-style="western"><surname>Candido</surname><given-names>DDA</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genomics and epidemiology of a the P.1 novel SARS-COV-2 lineage in Manaus, Brazil</article-title>. <source>Science</source> (<year>2021</year>) <volume>372</volume>:<page-range>815&#8211;821</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abh2644</pub-id><pub-id pub-id-type="pmcid">PMC8139423</pub-id><pub-id pub-id-type="pmid">33853970</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>NR</given-names></name><name name-style="western"><surname>Claro</surname><given-names>IM</given-names></name><etal/></person-group>. <source>Genomic characterisation of an emergent SARS-CoV-2 lineage in manaus: Preliminary findings</source> (<year>2021</year>). <publisher-name>virological.org</publisher-name>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://virological.org/t/genomic-characterisation-of-anemergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586">https://virological.org/t/genomic-characterisation-of-anemergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586</uri> (Accessed <date-in-citation content-type="access-date">February 14, 2022</date-in-citation>).</mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujino</surname><given-names>T</given-names></name><name name-style="western"><surname>Nomoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Kutsuna</surname><given-names>S</given-names></name><name name-style="western"><surname>Ujiie</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Sato</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Novel sars-COV-2 variant in travelers from Brazil to Japan</article-title>. <source>Emerging Infect Dis</source> (<year>2021</year>) <volume>27</volume>:<page-range>1243&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3201/eid2704.210138</pub-id><pub-id pub-id-type="pmcid">PMC8007308</pub-id><pub-id pub-id-type="pmid">33567247</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#228;f</surname><given-names>T</given-names></name><name name-style="western"><surname>Bello</surname><given-names>G</given-names></name><name name-style="western"><surname>Venas</surname><given-names>TM</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>EC</given-names></name><name name-style="western"><surname>Paix&#227;o</surname><given-names>AC</given-names></name><name name-style="western"><surname>Appolinario</surname><given-names>LR</given-names></name><etal/></person-group>. <article-title>Identification of a novel SARS-COV-2 p.1 sub-lineage in Brazil provides new insights about the mechanisms of emergence of variants of concern</article-title>. <source>Virus Evol</source> (<year>2021</year>) <volume>7</volume>:<elocation-id>eab091</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ve/veab091</pub-id><pub-id pub-id-type="pmcid">PMC8754780</pub-id><pub-id pub-id-type="pmid">35039782</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <source>SARS-CoV-2 variant classifications and definitions</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fvariant-info.html">https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fvariant-info.html</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="webpage"><source>Global virus network. delta (B.1.617.2)</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://gvn.org/covid-19/delta-b-1-617-2/">https://gvn.org/covid-19/delta-b-1-617-2/</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>PS-W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Sibai</surname><given-names>M</given-names></name><name name-style="western"><surname>Solis</surname><given-names>D</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>F</given-names></name><name name-style="western"><surname>Iwai</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Evaluation of a rapid and accessible reverse transcription-quantitative PCR approach for SARS-COV-2 variant of concern identification</article-title>. <source>J Clin Microbiol</source> (<year>2022</year>) <volume>60</volume>:<elocation-id>2</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1128/jcm.00178-22</pub-id><pub-id pub-id-type="pmcid">PMC9119066</pub-id><pub-id pub-id-type="pmid">35465708</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Deng</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Viral infection and transmission in a large, well-traced outbreak caused by the SARS-COV-2 delta variant</article-title>. <source>Nat Commun</source> (<year>2022</year>) <volume>13</volume>:<fpage>460</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-022-28089-y</pub-id><pub-id pub-id-type="pmid">35075154</pub-id><pub-id pub-id-type="pmcid">PMC8786931</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <source>Improving communications around vaccine breakthrough and vaccine effectiveness</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://context-cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165">https://context-cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).</mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>SW</given-names></name><name name-style="western"><surname>Chiew</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ang</surname><given-names>LW</given-names></name><name name-style="western"><surname>Mak</surname><given-names>T-M</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L</given-names></name><name name-style="western"><surname>Toh</surname><given-names>MP</given-names></name><etal/></person-group>. <article-title>Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) variants of concern: A retrospective cohort study comparing B.1.1.7 (alpha), b.1.351 (beta) and B.1.617.2 (delta)</article-title>. <source>Clin Infect Dis</source> (<year>2021</year>) <volume>2021</volume>:<elocation-id>ciab721</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1093/cid/ciab721</pub-id><pub-id pub-id-type="pmcid">PMC8522361</pub-id><pub-id pub-id-type="pmid">34423834</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>UC Health</collab></person-group>. <source>The delta variant</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uchealth.org/services/infectious-diseases/coronavirus-covid-19/the-delta-variant-of-covid-19/">https://www.uchealth.org/services/infectious-diseases/coronavirus-covid-19/the-delta-variant-of-covid-19/</uri> (Accessed <date-in-citation content-type="access-date">April 6, 2022</date-in-citation>).</mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohandas</surname><given-names>S</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></name><name name-style="western"><surname>Shete</surname><given-names>A</given-names></name><name name-style="western"><surname>Nyayanit</surname><given-names>D</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></name><name name-style="western"><surname>Lole</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 delta variant pathogenesis and host response in Syrian hamsters</article-title>. <source>Viruses</source> (<year>2021</year>) <volume>13</volume>:<elocation-id>1773</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/v13091773</pub-id><pub-id pub-id-type="pmid">34578354</pub-id><pub-id pub-id-type="pmcid">PMC8473140</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheikh</surname><given-names>A</given-names></name><name name-style="western"><surname>McMenamin</surname><given-names>J</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>C</given-names></name></person-group>. <article-title>SARS-CoV-2 delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness</article-title>. <source>Lancet</source> (<year>2021</year>) <volume>397</volume>:<page-range>2461&#8211;2</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(21)01358-1</pub-id><pub-id pub-id-type="pmcid">PMC8201647</pub-id><pub-id pub-id-type="pmid">34139198</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khedar</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>K</given-names></name><name name-style="western"><surname>Ambaliya</surname><given-names>HC</given-names></name><name name-style="western"><surname>Mathur</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>JB</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>KK</given-names></name><etal/></person-group>. <article-title>Greater covid-19 severity and mortality in hospitalized patients in second (Delta variant) wave compared to the first: Single centre prospective study in India</article-title>. <source>medRxiv</source> (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.09.03.21263091</pub-id><pub-id pub-id-type="pmid">37449685</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Bappy</surname><given-names>MH</given-names></name></person-group>. <article-title>On the delta plus variant of SARS-COV-2</article-title>. <source>Eur J Med Health Sci</source> (<year>2021</year>) <volume>3</volume>:<page-range>52&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.24018/ejmed.2021.3.6.1134</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kannan</surname><given-names>SR</given-names></name><name name-style="western"><surname>Spratt</surname><given-names>AN</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AR</given-names></name><name name-style="western"><surname>Naqvi</surname><given-names>SH</given-names></name><name name-style="western"><surname>Chand</surname><given-names>HS</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>TP</given-names></name><etal/></person-group>. <article-title>Evolutionary analysis of the delta and delta plus variants of the SARS-COV-2 viruses</article-title>. <source>J Autoimmun</source> (<year>2021</year>) <volume>124</volume>:<elocation-id>102715</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jaut.2021.102715</pub-id><pub-id pub-id-type="pmid">34399188</pub-id><pub-id pub-id-type="pmcid">PMC8354793</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>KP</given-names></name><name name-style="western"><surname>Ho</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K-C</given-names></name><name name-style="western"><surname>Ching</surname><given-names>RH</given-names></name><name name-style="western"><surname>Lai</surname><given-names>K-L</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 omicron variant replication in human bronchus and lung ex vivo</article-title>. <source>Nature</source> (<year>2022</year>) <volume>603</volume>:<page-range>715&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-022-04479-6</pub-id><pub-id pub-id-type="pmid">35104836</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="webpage"><source>Discovery health south africa&#8217;s largest private health insurance. real-world analysis of omicron outbreak based on 211 000 COVID-19 test results in south Africa, including collaboration with the south Africa</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.discovery.co.za/corporate/newsroom#/documents/presentation-deck-omicron-insights-final-14-december-2021-at-08h00-dot-pdf-417949">https://www.discovery.co.za/corporate/newsroom#/documents/presentation-deck-omicron-insights-final-14-december-2021-at-08h00-dot-pdf-417949</uri> (Accessed <date-in-citation content-type="access-date">April 10, 2022</date-in-citation>).</mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="webpage"><source>Public health ontario. COVID-19 variant of concern omicron (B.1.1.529): Risk assessment, January 12, 2022</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.publichealthontario.ca/-/media/documents/ncov/voc/2022/01/covid-19-omicron-b11529-risk-assessment-jan-12.pdf?sc_lang=en%2523:~:text=Since%25252520the%25252520last%25252520Risk%25252520Assessment%2525252C%25252520more%25252520evidence%25252520has%25252520emerged%25252520demonstrating,term%25252520protection%25252520against%25252520symptomatic%25252520Omicron">https://www.publichealthontario.ca/-/media/documents/ncov/voc/2022/01/covid-19-omicron-b11529-risk-assessment-jan-12.pdf?sc_lang=en%2523:~:text=Since%25252520the%25252520last%25252520Risk%25252520Assessment%2525252C%25252520more%25252520evidence%25252520has%25252520emerged%25252520demonstrating,term%25252520protection%25252520against%25252520symptomatic%25252520Omicron</uri> (Accessed <date-in-citation content-type="access-date">April 10, 2022</date-in-citation>).</mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="webpage"><source>The united states food and drug administration. SARS-CoV-2 viral mutations: Impact on COVID-19 tests</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact">https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact</uri> (Accessed <date-in-citation content-type="access-date">April 10, 2022</date-in-citation>).</mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>The United States Food and Drug Administration</collab></person-group>. <source>Revogene SARS-CoV-2 - letter of authorization</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/154057/download">https://www.fda.gov/media/154057/download</uri> (Accessed <date-in-citation content-type="access-date">April 10, 2022</date-in-citation>).</mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamasoba</surname><given-names>D</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>I</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>H</given-names></name><name name-style="western"><surname>Morioka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nao</surname><given-names>N</given-names></name><name name-style="western"><surname>Ito</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Virological characteristics of SARS-COV-2 BA.2 variant</article-title>. <source>. bioRxiv</source> (<year>2022</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2022.02.14.480335</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyngse</surname><given-names>FP</given-names></name><name name-style="western"><surname>Kirkeby</surname><given-names>CT</given-names></name><name name-style="western"><surname>Denwood</surname><given-names>M</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>LE</given-names></name><name name-style="western"><surname>M&#248;lbak</surname><given-names>K</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>Transmission of SARS-COV-2 omicron voc subvariants BA.1 and BA.2: Evidence from Danish households</article-title>. <source>bioRxiv</source> (<year>2022</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2022.01.28.22270044</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeyanathan</surname><given-names>M</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S</given-names></name><name name-style="western"><surname>Smaill</surname><given-names>F</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lichty</surname><given-names>BD</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z</given-names></name></person-group>. <article-title>Immunological considerations for covid-19 vaccine strategies</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>:<page-range>615&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41577-020-00434-6</pub-id><pub-id pub-id-type="pmcid">PMC7472682</pub-id><pub-id pub-id-type="pmid">32887954</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>JR</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>H</given-names></name><name name-style="western"><surname>Makinson</surname><given-names>R</given-names></name><name name-style="western"><surname>Morter</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>T Cell and antibody responses induced by a single dose of Chadox1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial</article-title>. <source>Nat Med</source> (<year>2020</year>) <volume>27</volume>:<page-range>270&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-020-01194-5</pub-id><pub-id pub-id-type="pmid">33335323</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>CL</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Koen</surname><given-names>AL</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant</article-title>. <source>N Engl J Med</source> (<year>2021</year>) <volume>384</volume>:<page-range>1885&#8211;98</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2102214</pub-id><pub-id pub-id-type="pmcid">PMC7993410</pub-id><pub-id pub-id-type="pmid">33725432</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="webpage"><source>COVID-19 real-time learning network. SARS-CoV-2 variants</source> (<year>2022</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.idsociety.org/covid-19-real-time-learning-network/emerging-variants/emerging-covid-19-variants/#Omicron">https://www.idsociety.org/covid-19-real-time-learning-network/emerging-variants/emerging-covid-19-variants/#Omicron</uri> (Accessed <date-in-citation content-type="access-date">April 10, 2022</date-in-citation>).</mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemens</surname><given-names>SA</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Emary</surname><given-names>KR</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name><name name-style="western"><surname>Ratcliff</surname><given-names>J</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Efficacy of Chadox1 nCoV-19 (AZD1222) vaccine against SARS-COV-2 lineages circulating in Brazil</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>:<fpage>5861</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s1467-021-25982-w</pub-id><pub-id pub-id-type="pmid">34615860</pub-id><pub-id pub-id-type="pmcid">PMC8494913</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Nasreen</surname><given-names>S</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>ME</given-names></name><name name-style="western"><surname>Buchan</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>Effectiveness of BNT162B2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-COV-2 infection and severe COVID-19 outcomes in Ontario, Canada: Test negative design study</article-title>. <source>BMJ</source> (<year>2021</year>) <volume>374</volume>:<elocation-id>1943</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/bmj.n1943</pub-id><pub-id pub-id-type="pmcid">PMC8377789</pub-id><pub-id pub-id-type="pmid">34417165</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hitchings</surname><given-names>MD</given-names></name><name name-style="western"><surname>Ranzani</surname><given-names>OT</given-names></name><name name-style="western"><surname>Dorion</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#8217;Agostini</surname><given-names>TL</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>RC</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>OF</given-names></name><etal/></person-group>. <article-title>Effectiveness of chadox1 vaccine in older adults during SARS-COV-2 gamma variant circulation in s&#227;o paulo</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>:<fpage>6220</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-26459-6</pub-id><pub-id pub-id-type="pmid">34711813</pub-id><pub-id pub-id-type="pmcid">PMC8553924</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez Bernal</surname><given-names>J</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>R</given-names></name><name name-style="western"><surname>Thelwall</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant</article-title>. <source>New Engl J Med</source> (<year>2021</year>) <volume>385</volume>:<page-range>585&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2108891</pub-id><pub-id pub-id-type="pmcid">PMC8314739</pub-id><pub-id pub-id-type="pmid">34289274</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mlcochova</surname><given-names>P</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>SA</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>MS</given-names></name><name name-style="western"><surname>Papa</surname><given-names>G</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>IA</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 B.1.617.2 delta variant replication and immune evasion</article-title>. <source>Nature</source> (<year>2021</year>) <volume>599</volume>:<page-range>114&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03944-y</pub-id><pub-id pub-id-type="pmcid">PMC8566220</pub-id><pub-id pub-id-type="pmid">34488225</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheikh</surname><given-names>A</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>C</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B</given-names></name></person-group>. <article-title>BNT162B2 and Chadox1 nCoV-19 vaccine effectiveness against death from the delta variant</article-title>. <source>New Engl J Med</source> (<year>2021</year>) <volume>385</volume>:<page-range>2195&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmc2113864</pub-id><pub-id pub-id-type="pmcid">PMC8552534</pub-id><pub-id pub-id-type="pmid">34670038</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>N</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J</given-names></name><name name-style="western"><surname>Kirsebom</surname><given-names>F</given-names></name><name name-style="western"><surname>Toffa</surname><given-names>S</given-names></name><name name-style="western"><surname>Rickeard</surname><given-names>T</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Covid-19 vaccine effectiveness against the omicron (b.1.1.529) variant</article-title>. <source>New Engl J Med</source> (<year>2022</year>) <volume>386</volume>:<page-range>1532&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2119451</pub-id><pub-id pub-id-type="pmcid">PMC8908811</pub-id><pub-id pub-id-type="pmid">35249272</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A</given-names></name><name name-style="western"><surname>C&#225;rdenas</surname><given-names>V</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19</article-title>. <source>New Engl J Med</source> (<year>2021</year>) <volume>384</volume>:<page-range>2187&#8211;201</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2101544</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id><pub-id pub-id-type="pmid">33882225</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephenson</surname><given-names>KE</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>AM</given-names></name><name name-style="western"><surname>Heerwegh</surname><given-names>D</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Immunogenicity of the Ad26.COV2.S vaccine for covid-19</article-title>. <source>JAMA</source> (<year>2021</year>) <volume>325</volume>:<fpage>1535</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2021.3645</pub-id><pub-id pub-id-type="pmid">33704352</pub-id><pub-id pub-id-type="pmcid">PMC7953339</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>SH</given-names></name><name name-style="western"><surname>Mansatta</surname><given-names>K</given-names></name><name name-style="western"><surname>Mallett</surname><given-names>G</given-names></name><name name-style="western"><surname>Harris</surname><given-names>V</given-names></name><name name-style="western"><surname>Emary</surname><given-names>KR</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name></person-group>. <article-title>What defines an efficacious COVID-19 vaccine? a review of the challenges assessing the clinical efficacy of vaccines against SARS-COV-2</article-title>. <source>Lancet Infect Dis</source> (<year>2021</year>) <volume>21</volume>:<page-range>26&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s1473-3099(20)30773-8</pub-id><pub-id pub-id-type="pmcid">PMC7837315</pub-id><pub-id pub-id-type="pmid">33125914</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Borducchi</surname><given-names>EN</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>LH</given-names></name><etal/></person-group>. <article-title>Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans</article-title>. <source>Nature</source> (<year>2021</year>) <volume>596</volume>:<page-range>268&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03681-2</pub-id><pub-id pub-id-type="pmcid">PMC8357629</pub-id><pub-id pub-id-type="pmid">34107529</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Nair</surname><given-names>MS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Iketani</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Antibody resistance of SARS-COV-2 variants B.1.351 and B.1.1.7</article-title>. <source>Nature</source> (<year>2021</year>) <volume>593</volume>:<page-range>130&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03398-2</pub-id><pub-id pub-id-type="pmid">33684923</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Werner</surname><given-names>AP</given-names></name><name name-style="western"><surname>Moliva</surname><given-names>JI</given-names></name><name name-style="western"><surname>Koch</surname><given-names>M</given-names></name><name name-style="western"><surname>Choi</surname><given-names>A</given-names></name><name name-style="western"><surname>Stewart-Jones</surname><given-names>GB</given-names></name><etal/></person-group>. <article-title>MRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-COV-2 variants</article-title>. <source>bioRxiv</source> (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.01.25.427948</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collier</surname><given-names>DA</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>IATM</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Datir</surname><given-names>R</given-names></name><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies</article-title>. <source>Nature</source> (<year>2021</year>) <volume>593</volume>:<page-range>136&#8211;141</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03412-7</pub-id><pub-id pub-id-type="pmcid">PMC7616976</pub-id><pub-id pub-id-type="pmid">33706364</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muik</surname><given-names>A</given-names></name><name name-style="western"><surname>Wallisch</surname><given-names>A-K</given-names></name><name name-style="western"><surname>S&#228;nger</surname><given-names>B</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>KA</given-names></name><name name-style="western"><surname>M&#252;hl</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Neutralization of SARS-COV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine&#8211;elicited human sera</article-title>. <source>Science</source> (<year>2021</year>) <volume>371</volume>:<page-range>1152&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abg6105</pub-id><pub-id pub-id-type="pmcid">PMC7971771</pub-id><pub-id pub-id-type="pmid">33514629</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polinski</surname><given-names>JM</given-names></name><name name-style="western"><surname>Weckstein</surname><given-names>AR</given-names></name><name name-style="western"><surname>Batech</surname><given-names>M</given-names></name><name name-style="western"><surname>Kabelac</surname><given-names>C</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>T</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Durability of the single-dose Ad26.COV2.S vaccine in the prevention of COVID-19 infections and hospitalizations in the US before and during the delta variant surge</article-title>. <source>JAMA Network Open</source> (<year>2022</year>) <volume>5</volume>:<fpage>e222959</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.2959</pub-id><pub-id pub-id-type="pmid">35297969</pub-id><pub-id pub-id-type="pmcid">PMC8931562</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jongeneelen</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaszas</surname><given-names>K</given-names></name><name name-style="western"><surname>Veldman</surname><given-names>D</given-names></name><name name-style="western"><surname>Huizingh</surname><given-names>J</given-names></name><name name-style="western"><surname>van der Vlugt</surname><given-names>R</given-names></name><name name-style="western"><surname>Schouten</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Ad26.COV2.S elicited neutralizing activity against delta and other SARS-COV-2 variants of concern</article-title>. <source>bioRxiv</source> (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.07.01.450707</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>F</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F</given-names></name><name name-style="western"><surname>Weisblum</surname><given-names>Y</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>J</given-names></name><name name-style="western"><surname>Bednarski</surname><given-names>E</given-names></name><name name-style="western"><surname>Cho</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Plasma neutralization of the SARS-COV-2 omicron variant</article-title>. <source>New Engl J Med</source> (<year>2022</year>) <volume>386</volume>:<fpage>599</fpage>&#8211;<lpage>601</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmc2119641</pub-id><pub-id pub-id-type="pmid">35030645</pub-id><pub-id pub-id-type="pmcid">PMC8757565</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameroni</surname><given-names>E</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>JE</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>LE</given-names></name><name name-style="western"><surname>Saliba</surname><given-names>C</given-names></name><name name-style="western"><surname>Zepeda</surname><given-names>SK</given-names></name><name name-style="western"><surname>Culap</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Broadly neutralizing antibodies overcome SARS-COV-2 omicron antigenic shift</article-title>. <source>Nature</source> (<year>2021</year>) <volume>602</volume>:<page-range>664&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-04386-2</pub-id><pub-id pub-id-type="pmcid">PMC9531318</pub-id><pub-id pub-id-type="pmid">35016195</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name><name name-style="western"><surname>Mattiuzzi</surname><given-names>C</given-names></name><name name-style="western"><surname>Henry</surname><given-names>BM</given-names></name></person-group>. <article-title>Neutralizing potency of covid-19 vaccines against the SARS-COV-2 omicron (b.1.1.529) variant</article-title>. <source>J Med Virol</source> (<year>2022</year>) <volume>94</volume>:<page-range>1799&#8211;802</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jmv.27575</pub-id><pub-id pub-id-type="pmcid">PMC9015583</pub-id><pub-id pub-id-type="pmid">34988998</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolter</surname><given-names>N</given-names></name><name name-style="western"><surname>Jassat</surname><given-names>W</given-names></name><name name-style="western"><surname>Walaza</surname><given-names>S</given-names></name><name name-style="western"><surname>Welch</surname><given-names>R</given-names></name><name name-style="western"><surname>Moultrie</surname><given-names>H</given-names></name><name name-style="western"><surname>Groome</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Early assessment of the clinical severity of the SARS-COV-2 omicron variant in south Africa</article-title>. <source>medRxiv</source> (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.12.21.21268116</pub-id><pub-id pub-id-type="pmcid">PMC8769664</pub-id><pub-id pub-id-type="pmid">35065011</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="webpage"><source>Discovery health south africa&#8217;s largest private health insurance. discovery health, south africa&#8217;s largest private health insurance administrator, releases at-scale, real-world analysis of omicron outbreak based on 211 000 COVID-19 test results in south Africa, including collaboration with the south Africa</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.discovery.co.za/corporate/newsroom#/documents/presentation-deck-omicron-insights-final-14-december-2021-at-08h00-dot-pdf-417949">https://www.discovery.co.za/corporate/newsroom#/documents/presentation-deck-omicron-insights-final-14-december-2021-at-08h00-dot-pdf-417949</uri> (Accessed <date-in-citation content-type="access-date">April 11, 2022</date-in-citation>).</mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>McMahan</surname><given-names>K</given-names></name><name name-style="western"><surname>Jacob-Dolan</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Vaccine protection against the SARS-CoV-2 omicron variant in macaques</article-title>. <source>Cell</source> (<year>2022</year>) <volume>185</volume>:<page-range>1549&#8211;1555</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2022.03.024</pub-id><pub-id pub-id-type="pmcid">PMC8926910</pub-id><pub-id pub-id-type="pmid">35427477</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collier A-ris</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>McMahan</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Maron</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>Differential kinetics of immune responses elicited by COVID-19 vaccines</article-title>. <source>New Engl J Med</source> (<year>2021</year>) <volume>385</volume>:<page-range>2010&#8211;2</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmc2115596</pub-id><pub-id pub-id-type="pmcid">PMC8531985</pub-id><pub-id pub-id-type="pmid">34648703</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sablerolles</surname><given-names>RSG</given-names></name><name name-style="western"><surname>Rietdijk</surname><given-names>WJR</given-names></name><name name-style="western"><surname>Goorhuis</surname><given-names>A</given-names></name><name name-style="western"><surname>Postma</surname><given-names>DF</given-names></name><name name-style="western"><surname>Visser</surname><given-names>LG</given-names></name><name name-style="western"><surname>Geers</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S priming</article-title>. <source>New Engl J Med</source> (<year>2022</year>) <volume>386</volume>:<page-range>951&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2116747</pub-id><pub-id pub-id-type="pmcid">PMC8796791</pub-id><pub-id pub-id-type="pmid">35045226</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atmar</surname><given-names>RL</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Deming</surname><given-names>ME</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Branche</surname><given-names>AR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Heterologous SARS-CoV-2 booster vaccinations - preliminary report</article-title>. <source>medRxiv</source> (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.10.10.21264827</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitchin</surname><given-names>D</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>SI</given-names></name><name name-style="western"><surname>van der Mescht</surname><given-names>MA</given-names></name><name name-style="western"><surname>Motlou</surname><given-names>T</given-names></name><name name-style="western"><surname>Mzindle</surname><given-names>N</given-names></name><name name-style="western"><surname>Moyo-Gwete</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against omicron and other SARS-COV-2 variants of concern</article-title>. <source>Cell Rep Med</source> (<year>2022</year>) <volume>3</volume>:<elocation-id>100535</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100535</pub-id><pub-id pub-id-type="pmid">35474744</pub-id><pub-id pub-id-type="pmcid">PMC8828412</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of the mrna-1273 SARS-COV-2 vaccine</article-title>. <source>New Engl J Med</source> (<year>2021</year>) <volume>384</volume>:<page-range>403&#8211;16</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id><pub-id pub-id-type="pmid">33378609</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>F</given-names></name><name name-style="western"><surname>Weisblum</surname><given-names>Y</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>CO</given-names></name><name name-style="western"><surname>Finkin</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>MRNA vaccine-elicited antibodies to SARS-COV-2 and circulating variants</article-title>. <source>Nature</source> (<year>2021</year>) <volume>592</volume>:<page-range>616&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03324-6</pub-id><pub-id pub-id-type="pmcid">PMC8503938</pub-id><pub-id pub-id-type="pmid">33567448</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woldemeskel</surname><given-names>BA</given-names></name><name name-style="western"><surname>Garliss</surname><given-names>CC</given-names></name><name name-style="western"><surname>Blankson</surname><given-names>JN</given-names></name></person-group>. <article-title>SARS-COV-2 mrna vaccines induce broad CD4+ T cell responses that recognize SARS-COV-2 variants and HCoV-NL63</article-title>. <source>J Clin Invest</source> (<year>2021</year>) <volume>131</volume>:<fpage>e149335</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1172/jci149335</pub-id><pub-id pub-id-type="pmcid">PMC8121504</pub-id><pub-id pub-id-type="pmid">33822770</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruxvoort</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Sy</surname><given-names>LS</given-names></name><name name-style="western"><surname>Qian</surname><given-names>L</given-names></name><name name-style="western"><surname>Ackerson</surname><given-names>BK</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Effectiveness of mrna-1273 against delta, mu, and other emerging variants of SARS-COV-2: Test negative case-control study</article-title>. <source>BMJ</source> (<year>2021</year>) <volume>375</volume>:<fpage>e068848</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1136/bmj-2021-068848</pub-id><pub-id pub-id-type="pmid">34911691</pub-id><pub-id pub-id-type="pmcid">PMC8671836</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chemaitelly</surname><given-names>H</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>HM</given-names></name><name name-style="western"><surname>Benslimane</surname><given-names>FM</given-names></name><name name-style="western"><surname>Al Khatib</surname><given-names>HA</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>MR</given-names></name><etal/></person-group>. <article-title>MRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar</article-title>. <source>Nat Med</source> (<year>2021</year>) <volume>27</volume>:<page-range>1614&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-021-01446-y</pub-id><pub-id pub-id-type="pmid">34244681</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Amin</surname><given-names>AB</given-names></name><name name-style="western"><surname>Ali</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hoots</surname><given-names>B</given-names></name><name name-style="western"><surname>Cadwell</surname><given-names>BL</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Covid-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence &#8212; 25 U.S. jurisdictions, April 4&#8211;December 25, 2021</article-title>. <source>MMWR Morb Mortal Weekly Rep</source> (<year>2022</year>) <volume>71</volume>:<page-range>132&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.15585/mmwr.mm7104e2</pub-id><pub-id pub-id-type="pmcid">PMC9351531</pub-id><pub-id pub-id-type="pmid">35085223</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>MG</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>K</given-names></name><name name-style="western"><surname>Irving</surname><given-names>SA</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>EA</given-names></name><name name-style="western"><surname>Griggs</surname><given-names>EP</given-names></name><name name-style="western"><surname>Gaglani</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effectiveness of a third dose of mrna vaccines against COVID-19&#8211;associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance &#8212; vision network, 10 states, august 2021&#8211;January 2022</article-title>. <source>MMWR Morb Mortal Weekly Rep</source> (<year>2022</year>) <volume>71</volume>:<page-range>139&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.15585/mmwr.mm7104e3</pub-id><pub-id pub-id-type="pmcid">PMC9351525</pub-id><pub-id pub-id-type="pmid">35085224</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Accorsi</surname><given-names>EK</given-names></name><name name-style="western"><surname>Britton</surname><given-names>A</given-names></name><name name-style="western"><surname>Fleming-Dutra</surname><given-names>KE</given-names></name><name name-style="western"><surname>Smith</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Shang</surname><given-names>N</given-names></name><name name-style="western"><surname>Derado</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Association between 3 doses of mrna COVID-19 vaccine and symptomatic infection caused by the SARS-COV-2 omicron and delta variants</article-title>. <source>JAMA</source> (<year>2022</year>) <volume>327</volume>:<fpage>639</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2022.0470</pub-id><pub-id pub-id-type="pmid">35060999</pub-id><pub-id pub-id-type="pmcid">PMC8848203</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferdinands</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>BE</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>PK</given-names></name><name name-style="western"><surname>DeSilva</surname><given-names>MB</given-names></name><name name-style="western"><surname>Irving</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Waning 2-dose and 3-dose effectiveness of mrna vaccines against COVID-19&#8211;associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance &#8212; vision network, 10 states, august 2021&#8211;January 2022</article-title>. <source>MMWR Morb Mortal Weekly Rep</source> (<year>2022</year>) <volume>71</volume>:<page-range>255&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.15585/mmwr.mm7107e2</pub-id><pub-id pub-id-type="pmcid">PMC8853475</pub-id><pub-id pub-id-type="pmid">35176007</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>HF</given-names></name><name name-style="western"><surname>Ackerson</surname><given-names>BK</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sy</surname><given-names>LS</given-names></name><name name-style="western"><surname>Talarico</surname><given-names>CA</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Effectiveness of mrna-1273 against SARS-COV-2 omicron and delta variants</article-title>. <source>Nat Med</source> (<year>2022</year>) <volume>28</volume>:<page-range>1063&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-022-01753-y</pub-id><pub-id pub-id-type="pmcid">PMC9117141</pub-id><pub-id pub-id-type="pmid">35189624</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doria-Rose</surname><given-names>NA</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>SD</given-names></name><name name-style="western"><surname>O&#8217;Dell</surname><given-names>S</given-names></name><name name-style="western"><surname>McDanal</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Booster of mrna-1273 strengthens SARS-COV-2 omicron neutralization</article-title>. <source>medRxiv</source> (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.12.15.21267805</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>RR</given-names></name><name name-style="western"><surname>Painter</surname><given-names>MM</given-names></name><name name-style="western"><surname>Apostolidis</surname><given-names>SA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>D</given-names></name><name name-style="western"><surname>Meng</surname><given-names>W</given-names></name><name name-style="western"><surname>Rosenfeld</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>MRNA vaccines induce durable immune memory to SARS-COV-2 and variants of concern</article-title>. <source>Science</source> (<year>2021</year>) <volume>374</volume>:<elocation-id>abm0829</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abm0829</pub-id><pub-id pub-id-type="pmid">34648302</pub-id><pub-id pub-id-type="pmcid">PMC9284784</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>A</given-names></name><name name-style="western"><surname>Koch</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>G</given-names></name><name name-style="western"><surname>Oestreicher</surname><given-names>J</given-names></name><name name-style="western"><surname>Legault</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Serum neutralizing activity of mrna-1273 against SARS-COV-2 variants</article-title>. <source>J Virol</source> (<year>2021</year>) <volume>95</volume>:<fpage>e0131321</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/jvi.01313-21</pub-id><pub-id pub-id-type="pmid">34549975</pub-id><pub-id pub-id-type="pmcid">PMC8577347</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Muik</surname><given-names>A</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Vogler</surname><given-names>I</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Covid-19 vaccine BNT162B1 elicits human antibody and th1 T cell responses</article-title>. <source>Nature</source> (<year>2020</year>) <volume>586</volume>:<page-range>594&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2814-7</pub-id><pub-id pub-id-type="pmid">32998157</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lef&#232;vre</surname><given-names>B</given-names></name><name name-style="western"><surname>Tondeur</surname><given-names>L</given-names></name><name name-style="western"><surname>Madec</surname><given-names>Y</given-names></name><name name-style="western"><surname>Grant</surname><given-names>R</given-names></name><name name-style="western"><surname>Lina</surname><given-names>B</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Beta sars-COV-2 variant and BNT162B2 vaccine effectiveness in long-term care facilities in France</article-title>. <source>Lancet Healthy Longevity</source> (<year>2021</year>) <volume>2</volume>:<page-range>685&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s2666-7568(21)00230-0</pub-id><pub-id pub-id-type="pmcid">PMC8457759</pub-id><pub-id pub-id-type="pmid">34580665</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of the BNT162B2 mrna covid-19 vaccine</article-title>. <source>New Engl J Med</source> (<year>2020</year>) <volume>383</volume>:<page-range>2603&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wall</surname><given-names>EC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>R</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>G</given-names></name><name name-style="western"><surname>Warchal</surname><given-names>S</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Neutralising antibody activity against SARS-COV-2 vocs B.1.617.2 and B.1.351 by BNT162B2 vaccination</article-title>. <source>Lancet</source> (<year>2021</year>) <volume>397</volume>:<page-range>2331&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0140-6736(21)01290-3</pub-id><pub-id pub-id-type="pmcid">PMC8175044</pub-id><pub-id pub-id-type="pmid">34090624</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="webpage"><source>All africa. SARS-Cov-2 omicron has extensive but incomplete escape of pfizer BNT162b2 elicited neutralization and requires ACE2 for infection</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://allafrica.com/view/resource/main/main/id/00130592.html">https://allafrica.com/view/resource/main/main/id/00130592.html</uri> (Accessed <date-in-citation content-type="access-date">April 13, 2022</date-in-citation>).</mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collie</surname><given-names>S</given-names></name><name name-style="western"><surname>Champion</surname><given-names>J</given-names></name><name name-style="western"><surname>Moultrie</surname><given-names>H</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>L-G</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name></person-group>. <article-title>Effectiveness of BNT162B2 vaccine against omicron variant in south Africa</article-title>. <source>New Engl J Med</source> (<year>2022</year>) <volume>386</volume>:<page-range>494&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmc2119270</pub-id><pub-id pub-id-type="pmcid">PMC8757569</pub-id><pub-id pub-id-type="pmid">34965358</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewer</surname><given-names>RC</given-names></name><name name-style="western"><surname>Ramadoss</surname><given-names>NS</given-names></name><name name-style="western"><surname>Lahey</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Jahanbani</surname><given-names>S</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>WH</given-names></name><name name-style="western"><surname>Lanz</surname><given-names>TV</given-names></name></person-group>. <article-title>BNT162b2 vaccine induces divergent b cell responses to SARS-COV-2 S1 and S2</article-title>. <source>Nat Immunol</source> (<year>2021</year>) <volume>23</volume>:<page-range>33&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41590-021-01088-9</pub-id><pub-id pub-id-type="pmcid">PMC8776031</pub-id><pub-id pub-id-type="pmid">34848871</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naaber</surname><given-names>P</given-names></name><name name-style="western"><surname>Tserel</surname><given-names>L</given-names></name><name name-style="western"><surname>Kangro</surname><given-names>K</given-names></name><name name-style="western"><surname>Sepp</surname><given-names>E</given-names></name><name name-style="western"><surname>J&#252;rjenson</surname><given-names>V</given-names></name><name name-style="western"><surname>Adamson</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study</article-title>. <source>Lancet Reg Health - Europe</source> (<year>2021</year>) <volume>10</volume>:<elocation-id>100208</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100208</pub-id><pub-id pub-id-type="pmid">34514454</pub-id><pub-id pub-id-type="pmcid">PMC8418937</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Muik</surname><given-names>A</given-names></name><name name-style="western"><surname>Vogler</surname><given-names>I</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans</article-title>. <source>Nature</source> (<year>2021</year>) <volume>595</volume>:<page-range>572&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03653-6</pub-id><pub-id pub-id-type="pmid">34044428</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemet</surname><given-names>I</given-names></name><name name-style="western"><surname>Kliker</surname><given-names>L</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>N</given-names></name><name name-style="western"><surname>Erster</surname><given-names>O</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Third BNT162B2 vaccination neutralization of SARS-COV-2 omicron infection</article-title>. <source>New Engl J Med</source> (<year>2022</year>) <volume>386</volume>:<page-range>492&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmc2119358</pub-id><pub-id pub-id-type="pmcid">PMC8823651</pub-id><pub-id pub-id-type="pmid">34965337</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrera</surname><given-names>G</given-names></name><name name-style="western"><surname>Picozza</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#8217;Orso</surname><given-names>S</given-names></name><name name-style="western"><surname>Placido</surname><given-names>R</given-names></name><name name-style="western"><surname>Pirronello</surname><given-names>M</given-names></name><name name-style="western"><surname>Verdiani</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>BNT162b2 vaccination induces durable SARS-COV-2&#8211;specific T cells with a stem cell memory phenotype</article-title>. <source>Sci Immunol</source> (<year>2021</year>) <volume>6</volume>:<elocation-id>eabl5344</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciimmunol.abl5344</pub-id><pub-id pub-id-type="pmid">34726470</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gattinoni</surname><given-names>L</given-names></name><name name-style="western"><surname>Speiser</surname><given-names>DE</given-names></name><name name-style="western"><surname>Lichterfeld</surname><given-names>M</given-names></name><name name-style="western"><surname>Bonini</surname><given-names>C</given-names></name></person-group>. <article-title>T Memory stem cells in health and disease</article-title>. <source>Nat Med</source> (<year>2017</year>) <volume>23</volume>:<fpage>18</fpage>&#8211;<lpage>27</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nm.4241</pub-id><pub-id pub-id-type="pmid">28060797</pub-id><pub-id pub-id-type="pmcid">PMC6354775</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fearon</surname><given-names>DT</given-names></name><name name-style="western"><surname>Manders</surname><given-names>P</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>SD</given-names></name></person-group>. <article-title>Arrested differentiation, the self-renewing memory lymphocyte, and vaccination</article-title>. <source>Science</source> (<year>2001</year>) <volume>293</volume>:<page-range>248&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.1062589</pub-id><pub-id pub-id-type="pmid">11452114</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luckey</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>D</given-names></name><name name-style="western"><surname>Goldrath</surname><given-names>AW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>IL</given-names></name><name name-style="western"><surname>Benoist</surname><given-names>C</given-names></name><name name-style="western"><surname>Mathis</surname><given-names>D</given-names></name></person-group>. <article-title>Memory T and memory b cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells</article-title>. <source>Proc Natl Acad Sci</source> (<year>2006</year>) <volume>103</volume>:<page-range>3304&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.0511137103</pub-id><pub-id pub-id-type="pmcid">PMC1413911</pub-id><pub-id pub-id-type="pmid">16492737</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciocca</surname><given-names>ML</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>BE</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>JK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JT</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>SL</given-names></name></person-group>. <article-title>Cutting edge: Asymmetric memory T cell division in response to rechallenge</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>:<page-range>4145&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1200176</pub-id><pub-id pub-id-type="pmcid">PMC3331961</pub-id><pub-id pub-id-type="pmid">22467651</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>SP</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V</given-names></name></person-group>. <article-title>Covid-19 vaccine: A comprehensive status report</article-title>. <source>Virus Res</source> (<year>2020</year>) <volume>288</volume>:<elocation-id>198114</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.virusres.2020.198114</pub-id><pub-id pub-id-type="pmid">32800805</pub-id><pub-id pub-id-type="pmcid">PMC7423510</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="webpage"><source>First post. race for COVID-19 vaccine: Covaxin and ZyCoV-d begin human trials in India, moderna publishes preliminary data from phase 1</source> (<year>2020</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.firstpost.com/health/race-for-covid-19-vaccine-covaxin-and-zycov-d-begin-human-trials-in-india-moderna-publishes-preliminary-data-from-phase-1-8600211.html/amp">https://www.firstpost.com/health/race-for-covid-19-vaccine-covaxin-and-zycov-d-begin-human-trials-in-india-moderna-publishes-preliminary-data-from-phase-1-8600211.html/amp</uri> (Accessed <date-in-citation content-type="access-date">April 14, 2022</date-in-citation>).</mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philippidis</surname><given-names>A</given-names></name></person-group>. <article-title>Six up-and-coming covid-19 vaccines</article-title>. <source>Genet Eng Biotechnol News</source> (<year>2021</year>) <volume>41</volume>:<fpage>6</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1089/gen.41.11.09</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="webpage"><source>Immunogenicity and safety study of SK sars-COV-2 recombinant nanoparticle vaccine (GBP510) adjuvanted with AS03 (COVID-19) - full text view. full text view - ClinicalTrialsgov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05007951">https://clinicaltrials.gov/ct2/show/NCT05007951</uri> (Accessed <date-in-citation content-type="access-date">May 22, 2022</date-in-citation>).</mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TR</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Immunogenicity of a DNA vaccine candidate for covid-19</article-title>. <source>Nat Commun</source> (<year>2020</year>) <volume>11</volume>:<fpage>2601</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-020-16505-0</pub-id><pub-id pub-id-type="pmid">32433465</pub-id><pub-id pub-id-type="pmcid">PMC7239918</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunkle</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>KL</given-names></name><name name-style="western"><surname>Gay</surname><given-names>CL</given-names></name><name name-style="western"><surname>&#193;&#241;ez</surname><given-names>G</given-names></name><name name-style="western"><surname>Adelglass</surname><given-names>JM</given-names></name><name name-style="western"><surname>Barrat Hern&#225;ndez</surname><given-names>AQ</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of NVX-cov2373 in adults in the united states and Mexico</article-title>. <source>New Engl J Med</source> (<year>2022</year>) <volume>386</volume>:<page-range>531&#8211;43</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2116185</pub-id><pub-id pub-id-type="pmcid">PMC8693692</pub-id><pub-id pub-id-type="pmid">34910859</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Clover Biopharmaceuticals</collab></person-group>. <source>SCB-2019 (CpG 1018/Alum) COVID-19 vaccine candidate</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cloverbiopharma.com/upload/pdf/SPECTRA-Data-Presentation_2021.09.22_FINAL_EN.pdf">https://www.cloverbiopharma.com/upload/pdf/SPECTRA-Data-Presentation_2021.09.22_FINAL_EN.pdf</uri> (Accessed <date-in-citation content-type="access-date">April 14, 2022</date-in-citation>).</mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>VBI Vaccines</collab></person-group>. <source>VBI vaccines announces initial positive phase 1 data for its eVLP vaccine candidate against COVID-19</source> (<year>2021</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vbivaccines.com/press-releases/covid-19-vaccine-phase-1-data/">https://www.vbivaccines.com/press-releases/covid-19-vaccine-phase-1-data/</uri> (Accessed <date-in-citation content-type="access-date">April 14, 2022</date-in-citation>).</mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morens</surname><given-names>DM</given-names></name><name name-style="western"><surname>Taubenberger</surname><given-names>JK</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name></person-group>. <article-title>Universal coronavirus vaccines &#8212; an urgent need</article-title>. <source>New Engl J Med</source> (<year>2022</year>) <volume>386</volume>:<page-range>297&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmp2118468</pub-id><pub-id pub-id-type="pmcid">PMC11000439</pub-id><pub-id pub-id-type="pmid">34910863</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></name></person-group>. <article-title>Nomenclature for immune correlates of protection after vaccination</article-title>. <source>Clin Infect Dis</source> (<year>2012</year>) <volume>54</volume>:<page-range>1615&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/cid/cis238</pub-id><pub-id pub-id-type="pmcid">PMC3348952</pub-id><pub-id pub-id-type="pmid">22437237</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karim</surname><given-names>SS</given-names></name></person-group>. <article-title>Vaccines and SARS-COV-2 variants: The urgent need for a correlate of protection</article-title>. <source>Lancet</source> (<year>2021</year>) <volume>397</volume>:<page-range>1263&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0140-6736(21)00468-2</pub-id><pub-id pub-id-type="pmcid">PMC7984864</pub-id><pub-id pub-id-type="pmid">33765410</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoury</surname><given-names>DS</given-names></name><name name-style="western"><surname>Cromer</surname><given-names>D</given-names></name><name name-style="western"><surname>Reynaldi</surname><given-names>A</given-names></name><name name-style="western"><surname>Schlub</surname><given-names>TE</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>AK</given-names></name><name name-style="western"><surname>Juno</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-COV-2 infection</article-title>. <source>Nat Med</source> (<year>2021</year>) <volume>27</volume>:<page-range>1205&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-021-01377-8</pub-id><pub-id pub-id-type="pmid">34002089</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dispinseri</surname><given-names>S</given-names></name><name name-style="western"><surname>Secchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Pirillo</surname><given-names>MF</given-names></name><name name-style="western"><surname>Tolazzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Borghi</surname><given-names>M</given-names></name><name name-style="western"><surname>Brigatti</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Neutralizing antibody responses to SARS-COV-2 in symptomatic COVID-19 is persistent and critical for survival</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>:<fpage>2670</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-22958-8</pub-id><pub-id pub-id-type="pmid">33976165</pub-id><pub-id pub-id-type="pmcid">PMC8113594</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trinit&#233;</surname><given-names>B</given-names></name><name name-style="western"><surname>Tarr&#233;s-Freixas</surname><given-names>F</given-names></name><name name-style="western"><surname>Rodon</surname><given-names>J</given-names></name><name name-style="western"><surname>Pradenas</surname><given-names>E</given-names></name><name name-style="western"><surname>Urrea</surname><given-names>V</given-names></name><name name-style="western"><surname>Marfil</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>SARS-COV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity</article-title>. <source>Sci Rep</source> (<year>2021</year>) <volume>11</volume>:<fpage>2608</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-021-81862-9</pub-id><pub-id pub-id-type="pmid">33510275</pub-id><pub-id pub-id-type="pmcid">PMC7843981</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Earle</surname><given-names>KA</given-names></name><name name-style="western"><surname>Ambrosino</surname><given-names>DM</given-names></name><name name-style="western"><surname>Fiore-Gartland</surname><given-names>A</given-names></name><name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></name><name name-style="western"><surname>Siber</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>Evidence for antibody as a protective correlate for covid-19 vaccines</article-title>. <source>Vaccine</source> (<year>2021</year>) <volume>39</volume>:<page-range>4423&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.05.063</pub-id><pub-id pub-id-type="pmcid">PMC8142841</pub-id><pub-id pub-id-type="pmid">34210573</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F</given-names></name></person-group>. <article-title>A correlate of protection for SARS-COV-2 vaccines is urgently needed</article-title>. <source>Nat Med</source> (<year>2021</year>) <volume>27</volume>:<page-range>1147&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-021-01432-4</pub-id><pub-id pub-id-type="pmid">34239135</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lafon</surname><given-names>E</given-names></name><name name-style="western"><surname>Diem</surname><given-names>G</given-names></name><name name-style="western"><surname>Witting</surname><given-names>C</given-names></name><name name-style="western"><surname>Zaderer</surname><given-names>V</given-names></name><name name-style="western"><surname>Bellmann-Weiler</surname><given-names>RM</given-names></name><name name-style="western"><surname>Reindl</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Potent SARS-CoV-2-Specific T cell immunity and low anaphylatoxin levels correlate with mild disease progression in COVID-19 patients</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>684014</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.684014</pub-id><pub-id pub-id-type="pmid">34194438</pub-id><pub-id pub-id-type="pmcid">PMC8237940</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMahan</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>LH</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Correlates of protection against SARS-COV-2 in rhesus macaques</article-title>. <source>Nature</source> (<year>2020</year>) <volume>590</volume>:<page-range>630&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-03041-6</pub-id><pub-id pub-id-type="pmcid">PMC7906955</pub-id><pub-id pub-id-type="pmid">33276369</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>King</surname><given-names>HA</given-names></name><name name-style="western"><surname>Elakhal-Naouar</surname><given-names>I</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A</given-names></name><name name-style="western"><surname>Peachman</surname><given-names>KK</given-names></name><name name-style="western"><surname>Macedo Cincotta</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A sars-COV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates</article-title>. <source>Sci Trans Med</source> (<year>2022</year>) <volume>14</volume>:<elocation-id>eabi5735</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.abi5735</pub-id><pub-id pub-id-type="pmid">34914540</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Broad and strong memory CD4+ and CD8+ T cells induced by SARS-COV-2 in UK convalescent individuals following covid-19</article-title>. <source>Nat Immunol</source> (<year>2020</year>) <volume>21</volume>:<page-range>1336&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41590-020-0782-6</pub-id><pub-id pub-id-type="pmcid">PMC7611020</pub-id><pub-id pub-id-type="pmid">32887977</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riou</surname><given-names>C</given-names></name><name name-style="western"><surname>du Bruyn</surname><given-names>E</given-names></name><name name-style="western"><surname>Stek</surname><given-names>C</given-names></name><name name-style="western"><surname>Daroowala</surname><given-names>R</given-names></name><name name-style="western"><surname>Goliath</surname><given-names>RT</given-names></name><name name-style="western"><surname>Abrahams</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Relationship of SARS-COV-2&#8211;specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection</article-title>. <source>J Clin Invest</source> (<year>2021</year>) <volume>131</volume>:<fpage>e149125</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1172/jci149125</pub-id><pub-id pub-id-type="pmcid">PMC8203446</pub-id><pub-id pub-id-type="pmid">33945513</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Moderbacher</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Targets of T cell responses to SARS-COV-2 coronavirus in humans with covid-19 disease and unexposed individuals</article-title>. <source>Cell</source> (<year>2020</year>) <volume>181</volume>:<page-range>1489&#8211;1501</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarke</surname><given-names>A</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J</given-names></name><name name-style="western"><surname>Methot</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Impact of SARS-COV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals</article-title>. <source>Cell Rep Med</source> (<year>2021</year>) <volume>2</volume>:<fpage>100355</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100355</pub-id><pub-id pub-id-type="pmid">34230917</pub-id><pub-id pub-id-type="pmcid">PMC8249675</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>S</given-names></name><name name-style="western"><surname>Sotzny</surname><given-names>F</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Na</surname><given-names>I-K</given-names></name><name name-style="western"><surname>Schmueck-Henneresse</surname><given-names>M</given-names></name><name name-style="western"><surname>Corman</surname><given-names>VM</given-names></name><etal/></person-group>. <article-title>HCoV- and SARS-COV-2 cross-reactive T cells in CVID patients</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>607918</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.607918</pub-id><pub-id pub-id-type="pmid">33424856</pub-id><pub-id pub-id-type="pmcid">PMC7785785</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamminen</surname><given-names>K</given-names></name><name name-style="western"><surname>Salminen</surname><given-names>M</given-names></name><name name-style="western"><surname>Blazevic</surname><given-names>V</given-names></name></person-group>. <article-title>Seroprevalence and SARS-COV-2 cross-reactivity of endemic coronavirus OC43 and 229e antibodies in Finnish children and adults</article-title>. <source>Clin Immunol</source> (<year>2021</year>) <volume>229</volume>:<elocation-id>108782</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.clim.2021.108782</pub-id><pub-id pub-id-type="pmid">34118402</pub-id><pub-id pub-id-type="pmcid">PMC8188772</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grobben</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Straten</surname><given-names>K</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>PJM</given-names></name><name name-style="western"><surname>Brinkkemper</surname><given-names>M</given-names></name><name name-style="western"><surname>Maisonnasse</surname><given-names>P</given-names></name><name name-style="western"><surname>Dereuddre-Bosquet</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Cross-reactive antibodies after SARS-COV-2 infection and vaccination</article-title>. <source>eLife</source> (<year>2021</year>) <volume>10</volume>:<fpage>e70330</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.7554/elife.70330</pub-id><pub-id pub-id-type="pmid">34812143</pub-id><pub-id pub-id-type="pmcid">PMC8610423</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>G</given-names></name><name name-style="western"><surname>W-ting</surname><given-names>He</given-names></name><name name-style="western"><surname>Callaghan</surname><given-names>S</given-names></name><name name-style="western"><surname>Anzanello</surname><given-names>F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ricketts</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Cross-reactive serum and memory b-cell responses to spike protein in SARS-COV-2 and endemic coronavirus infection</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>:<fpage>2938</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-23074-3</pub-id><pub-id pub-id-type="pmid">34011939</pub-id><pub-id pub-id-type="pmcid">PMC8134462</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sealy</surname><given-names>RE</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>JL</given-names></name></person-group>. <article-title>Cross-reactive immune responses toward the common cold human coronaviruses and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2): Mini-review and a murine study</article-title>. <source>Microorganisms</source> (<year>2021</year>) <volume>9</volume>:<elocation-id>1643</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/microorganisms9081643</pub-id><pub-id pub-id-type="pmid">34442723</pub-id><pub-id pub-id-type="pmcid">PMC8398386</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateus</surname><given-names>J</given-names></name><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Tarke</surname><given-names>A</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title>. <source>Science</source> (<year>2020</year>) <volume>4</volume>:<elocation-id>eabd3871</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><pub-id pub-id-type="pmcid">PMC7574914</pub-id><pub-id pub-id-type="pmid">32753554</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Bert</surname><given-names>N</given-names></name><name name-style="western"><surname>Tan</surname><given-names>AT</given-names></name><name name-style="western"><surname>Kunasegaran</surname><given-names>K</given-names></name><name name-style="western"><surname>Tham</surname><given-names>CY</given-names></name><name name-style="western"><surname>Hafezi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chia</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>SARS-COV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>. <source>Nature</source> (<year>2020</year>) <volume>584</volume>:<page-range>457&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2550-z</pub-id><pub-id pub-id-type="pmid">32668444</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name><name name-style="western"><surname>Grad</surname><given-names>YH</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S</given-names></name></person-group>. <article-title>Cross-reactive memory T cells and herd immunity to SARS-COV-2</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>(<issue>11</issue>):<page-range>709&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41577-020-00460-4</pub-id><pub-id pub-id-type="pmcid">PMC7537578</pub-id><pub-id pub-id-type="pmid">33024281</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name></person-group>. <article-title>Covid-19: Immunopathology and its implications for therapy</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>:<page-range>269&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41577-020-0308-3</pub-id><pub-id pub-id-type="pmcid">PMC7143200</pub-id><pub-id pub-id-type="pmid">32273594</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>T Cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice</article-title>. <source>J Virol</source> (<year>2010</year>) <volume>84</volume>:<page-range>9318&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/jvi.01049-10</pub-id><pub-id pub-id-type="pmcid">PMC2937604</pub-id><pub-id pub-id-type="pmid">20610717</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekine</surname><given-names>T</given-names></name><name name-style="western"><surname>Perez-Potti</surname><given-names>A</given-names></name><name name-style="western"><surname>Rivera-Ballesteros</surname><given-names>O</given-names></name><name name-style="western"><surname>Str&#229;lin</surname><given-names>K</given-names></name><name name-style="western"><surname>Gorin</surname><given-names>J-B</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19</article-title>. <source>Cell</source> (<year>2020</year>) <volume>183</volume>:<page-range>158&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.08.017</pub-id><pub-id pub-id-type="pmcid">PMC7427556</pub-id><pub-id pub-id-type="pmid">32979941</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heide</surname><given-names>J</given-names></name><name name-style="western"><surname>Schulte</surname><given-names>S</given-names></name><name name-style="western"><surname>Kohsar</surname><given-names>M</given-names></name><name name-style="western"><surname>Brehm</surname><given-names>TT</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Karsten</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Broadly directed SARS-COV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19</article-title>. <source>PloS Pathog</source> (<year>2021</year>) <volume>17</volume>:<fpage>e1009842</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1009842</pub-id><pub-id pub-id-type="pmid">34529740</pub-id><pub-id pub-id-type="pmcid">PMC8445433</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weingarten-Gabbay</surname><given-names>S</given-names></name><name name-style="western"><surname>Klaeger</surname><given-names>S</given-names></name><name name-style="western"><surname>Sarkizova</surname><given-names>S</given-names></name><name name-style="western"><surname>Pearlman</surname><given-names>LR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D-Y</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>KME</given-names></name><etal/></person-group>. <article-title>Profiling SARS-COV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame orfs</article-title>. <source>Cell</source> (<year>2021</year>) <volume>184</volume>:<page-range>3962&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.05.046</pub-id><pub-id pub-id-type="pmcid">PMC8173604</pub-id><pub-id pub-id-type="pmid">34171305</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatz</surname><given-names>SA</given-names></name><name name-style="western"><surname>Pohla</surname><given-names>H</given-names></name><name name-style="western"><surname>Schendel</surname><given-names>DJ</given-names></name></person-group>. <article-title>A PCR-SSP method to specifically select HLA-A*0201 individuals for immunotherapeutic studies</article-title>. <source>Tissue Antigens</source> (<year>2000</year>) <volume>55</volume>:<page-range>532&#8211;47</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1034/j.1399-0039.2000.550604.x</pub-id><pub-id pub-id-type="pmid">10902609</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>